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“Remain a beginner, like a child endowed with tremendous humility, patience and faith.  
Such should be our attitude towards the experiences life brings to us.  
Then we will keep on learning.  
For the mind to grow and become as big as the universe, we should first become a child.”  
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Coeliac disease (CD) is more common in children and adolescents with type 1 diabetes (T1D). Both 
diseases share the same high-risk genes: human leukocyte antigen (HLA) DQ2 and DQ8. Other factors 
than gluten intake and high-risk genes are necessary to develop CD. In Sweden, there was a dramatic 
increase in CD in young, otherwise healthy, children between 1984 and 1996 and this has been called the 
“Swedish epidemic of coeliac disease”, hereinafter referred as the Swedish CD epidemic. Over the last 
decade, the diagnostic guidelines for CD in children and adolescents have changed, but children with 
T1D are still not included in protocols to determine CD diagnosis without a biopsy, due to a lack of data.  
Aims  
The overall purpose of this dissertation was to expand current knowledge about CD in children and 
adolescents with T1D, with regard to the screening, diagnosis and prevalence of CD. One aim was  
to investigate the prevalence of CD in Swedish children and adolescents with T1D and compare the 
prevalence in individuals born before, during and after the Swedish CD epidemic. Another aim was  
to explore how CD screening in children and adolescents with T1D may be improved. 
Research strategy  
In Study I, we examined the medical records of 1,151 paediatric patients at a diabetes clinic in 
Stockholm to determine the prevalence of CD in children and adolescents with T1D, as well as the 
prevalence of CD in three subgroups. These were children born before, during and after the Swedish  
CD epidemic. In Study II, we investigated the prevalence of CD in patients with T1D at a Swedish 
national level, using several databases. We identified 1,642 children with T1D born during the Swedish 
CD epidemic (1992–1993) and 1,380 born after the epidemic (1997–1998). The total number of 
individuals born during these years was 430,374. In Studies III and IV, we used national cohort data 
from the Swedish prospective study Better Diabetes Diagnosis (BDD). In Study III, we analysed blood 
samples from 2,705 children and adolescents when they were diagnosed with T1D, to determine the 
links between HLA-DQ2 and HLA-DQ8, CD biomarker tissue transglutaminase (tTG) and diabetes 
autoantibodies. In Study IV, we analysed information from 2,035 children and adolescents with T1D, 
combined with data from the medical records kept by their diabetes clinics, to evaluate if high levels  
of tTG could predict CD. All the studies were approved by the Swedish Ethical Review Authority. 
Results  
Every tenth child and adolescent with T1D in Sweden also had CD. No difference in CD prevalence  
was found in children with T1D born before, during or after the Swedish CD epidemic. Many children 
were diagnosed with both diseases almost at the same time and the majority were diagnosed with CD 
within two years of being diagnosed with T1D. The CD biomarker tTG was related to the HLA high-risk 
genes DQ2 and DQ8, but not to diabetes autoantibodies. These risk-genes were absent in approximately 
8% of the children with T1D. When the CD biomarker tTG was 10 times above the upper limit of 
normal, it was accurate in predicting CD in children and adolescents with T1D.  
Conclusion  
The prevalence of CD in children and adolescents with T1D in Sweden was shown to be one of the 
highest in the world. Children with T1D were not affected by different gluten intake recommendations  
in infancy, unlike the general population during the Swedish CD epidemic. This finding can be taken 
into account when planning both long-term observational studies and interventional studies about how  
to prevent CD. HLA was only useful in identifying the T1D population that was not at-risk of 
developing CD. We recommend repeated CD screening in children with T1D and HLA DQ2 and/or 
DQ8, and suggest that the first two years after their T1D diagnosis is the most important time. It is also 
suggested that guidelines for diagnosing CD in screened children should also apply to children with 
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Type 1 diabetes (T1D) and coeliac disease (CD) are two very common chronic autoimmune 
diseases in children and adolescents. Over the past three decades, research about these 
diseases, and the combination of them, has intensified worldwide. At the beginning of 
2005, when the first study included in this thesis was designed, there was no Swedish or 
international consensus about screening for CD in children and adolescents with T1D.  
The screening methods that were available internationally were certainly getting better, 
with more accurate tests and better techniques for taking biopsies. Despite this, concerns 
had been highlighted about providing additional diagnoses of CD to children who already 
had T1D and this situation had led to comprehensive discussions by paediatric 
endocrinologists and gastroenterologists. It was against this background that I approached 
the research field of CD in T1D and came to play an active role in the design and execution 
of the studies included in this thesis. 
This thesis summarises four separate studies on children and adolescents with T1D and CD. 
The first part of the thesis provides a general introduction to the field. The next part 
compiles and discusses the results of these studies with regard to screening methods, 
diagnostic procedures and the prevalence of CD. The four original research studies, on 











2.1 COELIAC DISEASE 
2.1.1 History 
The history of CD contains interesting milestones and the first description of the disease 
dates back to around the second century AD. It emanated from the Fertile Crescent, which 
is an area between the Tigris, Euphrates and Upper Nile rivers. This was where the first 
cultivation of cereals, particularly wheat and barley, was recorded during the Neolithic 
period. The development of agriculture and cooking radically modified human diets, as up 
to that point they had relied on hunting and gathering. As far as we know, the first well-
described symptoms of CD were provided by Aretaeus of Cappadocian (circa 120-180 
AD), who was a notable Greek physician. He described the causes and signs of several 
diseases, including the disease we now call CD. The origin of the word coeliac derives from 
the Greek word koiliakós, which was used to refer to the intestinal involvement in this 
abdominal disease. When Aretaeus’ texts were found and translated, the word coeliac was 
broadly adopted (1, 2).  
Table 1, on the next page, summarises the most relevant scientific advances in CD 
throughout history.  
2.1.2 Definition 
CD is an immune-mediated disorder, which is triggered by exposure to gluten and related 
prolamins in genetically susceptible individuals (3, 4). It is characterised by clinical 
manifestations that are not always overtly present, CD biomarkers, such as specific 
antibodies against tissue transglutaminase, genetic markers such as human leucocyte 
antigen (HLA)-DQ2 and HLA-DQ8, and small intestine enteropathy (3). 
The Oslo definitions for CD-related terms, published in 2013, were a multidisciplinary 
attempt to evaluate the suggested definitions and terminology used to define the different 
presentations and forms of CD (5). 
The definition of symptomatic CD was clinical evidence of gastrointestinal and/or 
extraintestinal symptoms that were attributable to gluten. The so-called classical CD 
presentation included the manifestation of clinical signs and symptom of malabsorption. As 
malabsorption in CD is a result of the destruction of the mucosa in the small intestine, which 
stops the intestine from absorbing nutrients as usual, some of the symptoms in the paediatric 
population are loose stools (diarrhoea and steatorrhoea), abdominal distension, weight loss, 






Table 1. Milestones in the history of CD.  
Modified with permission from Coronel Rodriguez et al (6). 
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This differed from the definition of non-classical CD that included patients presenting 
without symptoms of malabsorption. The term subclinical CD is now deemed more 
acceptable than silent CD for individuals without signs or symptoms of CD (5). 
Furthermore, CD autoimmunity in an individual was defined as an increased level of CD 
biomarker at least twice, while potential CD corresponded to CD autoimmunity with a 
normal small intestinal mucosa. In addition, people who were genetically at-risk for CD were 
described as individuals with positive genetic tests for either of the CD risk genes (5). 
The definitions and diagnosis of CD in the population have usually been represented with the 




Figure 1. The 
iceberg model.  
The known CD cases  
are in the visible part  
of the iceberg, while  
the submerged part 
of the iceberg 
represents 





2.1.3 Incidence and prevalence  
CD is a common disease that affects individuals at all ages worldwide. About one in 100 
people in the western world have the disease (7) The number of people that are diagnosed 
with CD depends on several different factors. The prevalence of CD also varies within the 
same populations, which, in some cases, may depend on the design of the study to find 
individuals with CD, as many people with CD may have an undiagnosed disease (8). 
The prevalence of CD varies with regard to sex, age and location. CD is more common in 
females, as two out of three patients are girls or women (9-11). However, this sex disparity 
may be lower when the population is screened (8). CD can start at any age, although two 
peaks of CD onset are usually described: one in early childhood around the age of two and 
the other around the age of 30. In Sweden, the median age for a CD diagnosis in children and 
adolescents has increased from 1.0 year of age in the 1970s to 6.8 years in 2009 (11). In 
addition, the number of children with CD varies in different regions, within the same country 
(12, 13) and between neighbouring countries (14). Moreover, CD is increasing over time in 




Sweden has one of the highest prevalence figures of CD in the world (7). The disease is also 
one of the most common chronic diseases in children and young people in Sweden. A study 
that screened Swedish school children for CD found a prevalence of 3% (16). Furthermore, a 
prospective study carried out in four different countries that followed children who were 
genetically at-risk, showed that Swedish children had nearly double the risk of developing 
CD than North American children (17).  
2.1.4 Swedish epidemic of coeliac disease 
In Sweden, there was a dramatic increase in CD in young children between 1984 and 1996, 
when the number of cases of CD quadrupled. This period of time has been called "The 
Swedish epidemic of coeliac disease", hereinafter referred as the Swedish CD epidemic (18-
21). 
Paediatricians throughout Sweden diagnosed an increasing number of young children with 
CD. The cumulative incidence of CD reached higher levels than those previously reported, 
from one to four cases per 1,000 births. This increase in incidence, especially among children 
under two years of age, was followed by an abrupt decline (12, 18) (Figure 2). 
 
Figure 2. Incidence of CD per 
100,000 person-years, illustrating  
the incidence of CD in different 
ages from 1973-2003.  
Printed with kindly permission 
from Olsson et al and the 
publisher (12). 
 
During the Swedish CD epidemic the Swedish infant feeding recommendations changed with 
regard to time for gluten introduction. The national recommendations postponed gluten 
introduction from four to six months of age, which was the same period when breastfeeding 
was more likely to be discontinued. At the same time, the gluten content in infant milk 
cereals drinks and porridges was increased, in a move that was unrelated to the changes in the 
national recommendation (10). 
In 1996, the feeding recommendations changed again and they were almost the same as they 
were before 1986. These changes included a gradual introduction of gluten, preferably during 
breastfeeding, as well as a reduction in the gluten content of commercially available products 
for infants (18). After these new recommendations were implemented, the incidence of CD 
rapidly decreased, to similar levels as before the epidemic (10). These fluctuations stimulated 






The diagnosis of classical CD has been based on the clinical presentation, with signs and 
symptoms, the presence of CD biomarkers in peripheral blood and small intestine mucosal 
damage (22).  
During the few past decades, the tests for CD biomarkers have been improved. The CD 
biomarkers, which are based on serology, include the autoantibodies that have been showed 
to be present in high levels when the mucosal damage exists (23). One of the first tests that 
was made available focused on anti-gliadin antibodies (AGA). These were not as specific 
as the later tests that targeted endomysial autoantibodies (EMA). The accuracy of CD 
biomarkers has increased since tissue transglutaminase (tTG) immunoassays were 
introduced in the late 1990s (5, 24). These tests are constructed as immunoglobulin A (IgA) 
tests. In children with IgA deficiency, deaminated gliadin peptides antibodies of the 
immunoglobulin G (DGP) type may be used to diagnosis CD. The 2020 guidelines from the 
European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 
provided forest plots about the sensitivity and specificity of the available tests (22). 
In summary, the antibodies that have been the commonly used as CD biomarkers are as 
follows: 
• AGA antibodies: these are not very specific, but they were useful before the 
development of other CD biomarkers.  
• EMA antibodies: these target the enzyme transglutaminase which make them very 
specific, but less sensitive. They can be used as a confirmatory test due to their high 
specificity. 
• tTG antibodies: these show high sensitivity and specificity and their levels can be 
correlated with the degree of intestinal mucosal damage found in biopsies. They are 
the first choice due to their high sensitivity and good specificity. 
• DGP antibodies: these are directed against gluten fragments that have been 
deaminated by the tissue transglutaminase enzyme in the intestine. The antibody types 
that are most frequently used are those of the immunoglobulin G class, especially for 
IgA deficiency patients. 
Biopsy 
The purpose of biopsies is to identify the small intestine mucosal damage that is 
characteristic of CD. The pathological changes in the mucosa include increased number of 
intraepithelial lymphocytes, crypt hyperplasia and villous atrophy, which classification 
were described by Marsh (23, 25). These changes can only be observed by intestinal 
biopsies that are obtained after an upper gastrointestinal endoscopy. An older methodology 
was capsule biopsy, which is seldom used today. The assessment of histological damage is 
mostly graded according to the Marsh-Oberhüber criteria. These criteria report the degree 
of injury including inflammation and flattening of the villi of the mucosa in the small 




Figure 3. Schematic representation of mucosal damage to the small intestine.  
Marsh 0 represents normal mucosa with long villi and short crypts in the epithelial cells. 
Marsh 1 shows increased immune cells (intraepithelial lymphocytes). 
In Marsh 2 there are aggregating elongated crypts, so-called “deep valleys”.  
Marsh 3a/b/c correspond to different stadia of shortened villa, to complete villus atrophy, 
accompanied by more autoimmune cells and long crypts.  
Illustration inspired by “Celiakiboken” (28). 
 
However, it is worth mention that small bowel involvement could be patchy (areas with 
different degrees of damage) which makes a normal histological grade not a completely 
sure way to overruled CD in all cases (29, 30). These so called false negative biopsies have 
been discussed in the literature in the past decade (31, 32), and have encouraged other 
diagnostic approaches. One of the most important of these is the need to take several 
biopsies from both proximal and distal parts (22). Furthermore, histological damage is not 
always related to the patient's symptoms, that is, more damage does not translate into more 
symptoms, even if a correlation has been seen regarding CD biomarkers (23). 
Guidelines  
The first European diagnostic criteria for CD were introduced by ESPGHAN in 1969 (29, 
33). The next revision occurred in 1990, allowing clinicians to abandon the ESPGHAN 
1969 criteria of three mandatory biopsies (30).  
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The later the publication of the ESPGHAN 2012 guidelines marked a change in the 
diagnosis of CD. It opened up a new possibility in one of the algorithms: the option for 
clinicians to provide a CD diagnosis without an intestinal biopsy was accepted under 
certain circumstances (3). The no biopsy approach was recognised after reviewing the 
literature and noting that the serological tests showed an increase in sensitivity and positive 
predictive values (PPV) (34, 35). 
The criteria for allowing a no biopsy diagnosis were the following: tTG level 10 times 
above the upper limit of normal (ULN), a second test with elevated EMA and the presence 
of HLA risk genes (3). 
These criteria were only applicable for the children with symptoms. They did not consider 
children and adolescents with T1D, regardless of tTG levels, who were usually identified 
through screening, or among other groups of asymptomatic children (3).  
After the 2012 ESPGHAN guidelines were published (3) other international authorities 
chose to follow the recommendations, as stated in the United Kingdom guidelines (36), or 
argue against the no biopsy approach, as the North American Society for Pediatric 
Gastroenterology, Hepatology and Nutrition indicated in a clinical report (4).  
In the following years, several studies applied the ESPGHAN guidelines to ongoing, or 
retrospective, studies. New data on asymptomatic children, and how they could be included 
into the guidelines, were published (37-42). Most of these studies, and the others that were 
included in the assessment that led to the ESPGHAN 2020 guidelines (22), showed that CD 
could be diagnosed by the no biopsy approach, even in asymptomatic children. There were 
no studies with a high number of individuals with T1D in the ESPGHAN 2020 analysis and 
that was why these new guidelines were not able to address the possibility of a no biopsy 
approach for children and adolescents with T1D (22). 
It is important to understand that small bowel biopsies are by no means outdated as they 
still play a central part in diagnosing CD. For example, analysing biopsies is mandatory in 
children and adolescents with IgA deficiency or if the level of CD biomarkers does not 
meet the established criteria (22). 
 
2.1.6 Treatment 
CD cannot be cured and the only treatment that is currently available is a lifelong gluten-
free diet. Gluten is a protein found in various grains, such as wheat, rye and barley (5). The 
term gluten-free is defined by authorities both in Europe and North America and this covers 
foods items without the wheat proteins (gliadins and glutenins), barley (hordeins) and rye 
(secalins) and other hybrids, such as triticale cereals (43, 44). 
Most of the individuals with CD who follow the dietary advice they are given recover, 
because the intestinal mucosal damage heals when they avoid gluten. In the Oslo definitions, 
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persistent or recurrent symptoms due to malabsorption, despite a gluten-free diet for more 
than 12 months, was defined as refractory CD (5). This entity is very uncommon, as it only 
affects 0.3% of all patients diagnosed with CD, and it is even more uncommon in children 
and adolescents (45). 
Undetected or untreated CD has been associated with a number of symptoms and 
complications. This complications include iron-deficiency, retarded height and weight 
development and delayed puberty in children and adolescents. Some of the long-term 
complications are osteoporosis, depression, and, in rare cases, an unusual type of bowel 
cancer (lymphoma), and lower fertility or infertility (8, 46). 
 
2.1.7 Immunological pathogenesis 
CD is an autoimmune disease that primordially affects the small intestine mucosa (45).  
In CD, the initiators of the autoimmune cascade are the gluten peptides that are partially 
digested into gliadins. In the lumen of the intestine, these peptides are carried across the 
epithelial barrier and deaminated by tissue transglutaminase enzymes. Deamidated gliadin 
peptides are subsequently recognized by, and bind to, cells porting HLA-DQ2 and/or  
HLA-DQ8 antigens in their surface, the so-called antigen presenting cells (47).  
Under distinctive proinflammatory conditions, these antigen presenting cells are recognised 
by T cells that trigger the immune system activation. This activation promotes a maturation of 
B cells producing IgM, IgG and IgA antibodies against gliadin and tissue transglutaminase. 
In addition, T cells are also involved in the production of pro-inflammatory cytokines 
(interleukin-15, interferon γ and tumour necrosis factor α), which, in turn, probably further 
increase gut permeability and may accelerate the initiation of the enteropathy (48). 
 
2.1.8 Multifactorial aetiology 
The multifactorial aetiology of CD is a complex combination of, and interaction between, 
genetic and environmental factors (48). The adverse reaction to gluten can only occur if the 
high-risk genes are present (49, 50). However, having the high-risk genes HLA-DQ2 and/or 
HLA-DQ8, and being exposure to gluten, is not enough to develop CD. Other factors that 
determine whether someone develops CD appear to be involved in triggering the onset of the 
disease, but these are unknown to great extent (51) (Figure 4, on next page).  
In common with many others autoimmune diseases, CD has a strong hereditary component. It 
has been shown to occur in 10% of family members, and the concordance rates among 




Figure 4. In the 
aetiopathogenesis  
of CD, genetic and 
immunological factors 
interact in response to 
environmental factors, 
where a necessary but 
not sufficient factor is 
the intake of gluten.  
Figure inspired by 




The greatest genetic contributors are the previously mentioned HLA high-risk genes, located 
on the short arm of chromosome 6 (locus 6p21) (53). The genotype HLA-DQ2/DQ2 confers 
the most risk for developing CD (50). The HLA genotypes encode major histocompatibility 
complex (MHC) cell-surface membrane glycoproteins that bind antigens to present them to T 
cells receptors. In a figurative way, the risk-genes code for a type of presentation tools, as a 
“lock”, that allows the modified gluten-fragment (deaminated gliadin), the “key” to be tightly 
bound, and thus these complexes can be misinterpreted as dangerous and therefore activate 
the immune system (54, 55) (Figure 5). 
 
 
Figure 5. HLA DQ2/DQ8 and its role in the development of CD (simplified illustration). 
If HLA DQ2/DQ8 is not present (left), the gluten-fragment is not tightly bound by the HLA 
molecule on the antigen presenting cell and does not initiate any immune reaction. If HLA 
DQ2 and/or DQ8 are present (right), the gluten-fragment is bound firmly and an immune 
reaction may be provoked if other yet unknown conditions do also apply.  
Printed with kindly permission from Prof. Sybille Koletzko, “Celiac facts” (54). 
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Moreover, there are many other non-HLA-related genes that have been shown to be related to 
a higher risk for CD through genome-wide associations. Many of these genes have 
connections to T cells and B cells, which also contribute to the development of CD, even if 
the relevance of each of them seems to be limited or has a modest effect (56).  
With regard to environmental factors, the specific significance of these is still not well 
understood (14, 57). Some dietary factors that were recognized during observational studies 
were then well-studied in prospective and interventional multicentre studies. Early studies 
suggested that breastfeeding could reduce the risk of CD. However, two interventional 
studies in 2014 were unable to demonstrate that breastfeeding, or the time of gluten 
introduction in infancy, were effective in preventing CD (58, 59). These studies were 
randomized trials on children who had a high-risk of developing CD. In contrast, in 2019, 
two newly published cohort studies (60, 61) have suggested that the amount of gluten may 
actually be associated with future CD autoimmunity and CD development. The 2014 and 
2019 studies both included at-risk child populations. Nevertheless, there has only been one 
truly population-based study that focused on the duration of breastfeeding and when and how 
much gluten was introduced and that was a study from Norway, also published 2019 (62). 
The main finding of that study was that the risk of CD increased with each gram of extra 
gluten intake at the age of 18 months. Furthermore, the authors reported a higher risk when 
gluten was introduced after six months of age and stated that children with a longer period of 
breastfeeding had a lower intake of gluten in infancy. Interestingly, they noted a stronger 
association between the amount of gluten and the risk for CD in children with intermediate or 
low risk HLA for CD (62).  
Other factors related to pregnancy and the perinatal period have been explored in longitudinal 
studies. The assessments included parental smoking, maternal gluten intake and maternal 
drug consumption, but iron intake was the only factor that showed a correlation to a higher 
risk for CD. Even birth weight and the season of birth have been explored, but these factors 
did not contribute to major risks (14).  
Associations, and lack of associations, have been reported for various infectious diseases and 
their roles in triggering CD. In particular, gastrointestinal infections and the repeated use of 
antibiotics could play a potential role in the development of CD (14). The possible 
mechanism could be changes in the microbiome and the gastrointestinal micromilieu, which 
may be involved in the pathogenesis of CD (14). In a recent study, antibiotics treatment 
during the first year of life was positively associated with CD diagnosis in the Danish and 
Norwegian cohorts (63).  
In a similar way, vaccines may indirectly influence the risk of infections and the later risk of 
CD, but a Swedish study did not find a correlation between early vaccinations and the risk of 
CD (64). Particular attention has been given to the oral rotavirus vaccine. One population-
based cohort study found no higher risk of developing CD after vaccination (65). In addition, 
a randomized control trial reported that the prevalence of CD was lower in the rotavirus 
vaccinated group and it was suggested that the wild form of the virus may trigger CD (66).  
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2.2 TYPE 1 DIABETES 
2.2.1 History  
Diabetes is a disease that has been known since ancient times. The first reference appeared 
in the Ebers Papyrus (1500 BC). This Egyptian medical papyrus contained information 
about treatment for the condition’s main symptom: polyuria (67). 
In Hindu medicine, sticky urine with a sweet smell was described in the Vedas and called 
"madhumeha" (urine of honey). Sushruta, the father of Hindu medicine, distinguished a 
disease form that occurred in young people, leading to death, and another type that occurred 
in the elderly (1). 
In the second century A D, Aretaeus of Cappadocian described diabetes patients through 
their urinary symptoms, stating that "the sick never stop urinating". He called this disease 
"diabetes", from the Greek word siphon, "to run through” (67). 
Table 2, on the next page, briefly describes T1D in terms of the historical milestones and 
scientific advances.  
 
2.2.2 Definition 
Diabetes is a group of multifaceted metabolic disorders that cause chronic, elevated blood 
glucose levels. The definition of T1D is based on how diabetes is diagnosed.  
The latest guidelines from the International Society for Pediatric and Adolescent Diabetes 
(ISPAD) (68) state that: “The term diabetes mellitus describes a complex metabolic disorder 
characterized by chronic hyperglycaemia resulting from defects in insulin secretion, insulin 
action, or both”. This definition is in accordance with the 2007 definition from the American 
Diabetes Association (69), which also specifies that T1D is caused by an absolute deficiency 
of insulin secretion and that individuals at-risk for T1D can “be identified by serological 
evidence of an autoimmune pathologic process occurring in the pancreatic islets and by 
genetic markers”.  
 
2.2.3 Incidence 
T1D is the most common serious chronic disease in Swedish children (70). Sweden has the 
second highest incidence of T1D in the world, after Finland (71, 72). Around 50,000 
individuals have T1D in Sweden and about 7,000 are children and young people. About 800 
children are diagnosed with T1D in Sweden every year (73).  
In contrast to other autoimmune diseases, T1D affects slightly more boys in most populations 





Table 2. Milestones about the history of T1D (1, 67, 75). 
 
A rise in the incidence of T1D has been seen globally in the last few decades. About 96,000 
children are diagnosed with T1D in the world each year (72). Trends in the incidence of T1D 
vary markedly from country to country (68), possibly due to genetic variations and 
environmental differences in different populations (72). In Sweden, almost double number of 





Figure 6. The increased incidence  
of T1D in Sweden according to age at 
diagnosis.  
Reprinted with kindly permission from  







Two major hypotheses for the increasing incidence of T1D have been suggested. One is the 
hygiene hypothesis, which suggest that urban environments lack the microorganisms that 
used to stimulate the immune system. This loss of stimuli would result in an inappropriate 
immune activity seen in autoimmune diseases such as T1D (76). The other is the accelerator 
hypothesis, which advocates that insulin resistance and hyperglycaemia metabolically 
upregulate ß-cells, leading to glucotoxicity that accelerates the ß-cell loss and causes T1D in 
genetically susceptible individuals (77). Further investigations are still needed to validate 
these theories. Multiple trials aiming to prevent T1D development are ongoing or being 
planned which may help to identify additional causes (78). 
 
2.2.4 Diagnosis  
The classic symptoms that appear during the onset of T1D are increased thirst, large amounts 
of urine and weight loss. Other signs are fatigue and blurred vision (68). 
T1D is diagnosed by blood tests and blood glucose levels and tests for diabetes 
autoantibodies can help to distinguish between different types of diabetes (68, 69). 
An exact definition of blood glucose levels and diabetes has been provided by ISPAD (68):  
“A marked elevation of the blood glucose levels confirms the diagnosis of diabetes, including 
a random plasma glucose concentration ≥11.1 mmol/L (200 mg/dL) or fasting plasma 
glucose ≥7.0 mmol/L (≥126 mg/dL) in the presence of overt symptoms.”  
 
2.2.5 Treatment 
T1D cannot be cured at the moment. The only treatment that is currently available is to add 
insulin. The treatment goal is that the blood glucose level stabilises and stays within normal 
limits (70). 
Technological support has been at the forefront of research over the past decade (75). These 
technical advantages include insulin pumps and continuous glucose monitoring and the 
Yonas Berhan et al. Diabetes 2011;60:577-581
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ability to communicate glucose values to various applications. In addition, loop systems 
have been developed, which means that the blood glucose level in a sensor can help the 
insulin pump to decide the amount of insulin that is delivered (75). 
2.2.6 Immunological pathogenesis 
T1D is an organ-specific autoimmune disease that affects the pancreas. The pathogenesis of 
T1D is believed to include T cell activation, possibly through the presentation of modified 
peptides in the pancreas. Activated T cells promote the destruction of the insulin-producing 
ß-cells in the pancreas, which usually results in absolute insulin deficiency (48, 68). 
There are several antibodies that are important in T1D, but their roles seems to be related to 
the consequences of T1D, rather than the root causes. Autoantibodies to antigens of the 
pancreatic ß-cell are the first sign of disease and have been used as a predictive marker of the 
immunological process (79).  
The autoimmune markers involved in T1D include the 65KDa isoform of glutamic acid 
decarboxylase autoantibodies (GADA), insulinoma-associated-2 autoantibodies (IA-2A), 
insulin autoantibodies (IAA) and three types of zinc transporter-8 autoantibodies (ZnT8A). 
The presence of one or more of these autoantibodies, in addition to the clinical presentation, 
confirms T1D (68). Earlier studies have shown that approximately 93% of Swedish children 
with newly diagnosed T1D have at least one of these autoantibodies (80, 81). 
 
2.2.7 Multifactorial aetiology 
The multifactorial aetiology of T1D is a complex combination of, and interaction between, 




Figure 7. In the 
aetiopathogenesis of 
T1D, genetic and 
immunological factors 
interact in response to 
environmental factors. 
Figure inspired by 
“Celiac Facts”(54) 




Several genes have been linked with T1D by genome-wide association, and these include 
both highly susceptible and highly protective haplotypes (82). The HLA-DQ alleles have a 
well-established association to T1D risk (83, 84). The HLA region is responsible for up to 
50% of the genetic risk. The HLA-DQ2 and HLA-DQ8 haplotypes, alone, or in combination, 
are the strongest known genetic determinants for T1D and they confer a 5% absolute risk of 
diabetes at the age of 15 (85). Nearly 90% of the Scandinavian paediatric T1D population 
have one, or both, of these haplotypes (86). However, less than 10% of those children with 
the highest risk genotype (HLA-DQ2 or DQ8) will develop clinical diabetes (87). 
The complex genetic background of T1D also involves loci outside the HLA region (82). 
More than 40 non-HLA genes have been identified, including the INS insulin gene, PTPN22 
gene and CTLA4 gene (87), which all code interactions with the immune system. However, 
their effects on the pathogenesis is much smaller, and it has been suggested that they only 
modify the risk established by the HLA genotype (46). 
When it comes to the effect of the environment, two factors have particularly been associated 
with T1D in epidemiological and immunological studies. One is the exposure to enteroviral 
infections and the other is cows’ milk, latter with conflicting results (88). Other theories have 
included Vitamins D and E, while iron intake during pregnancy and in early childhood have 
not shown an association (89). These nutritional and infectious causes, and others, have been 
described in the literature, but their specific significance are still mainly undetermined in the 
aetiology of T1D (89). 
Evidence has suggested that the regulation of the gut immune system may be involved in 
the development of T1D (88). The role of Rotavirus, and rotavirus vaccination has been 
studied without consistent results (78), and recent studies have not been able to show any 
differences in T1D risks after Rotavirus vaccination (65, 90, 91). 
 
2.3 COMORBIDITY OF COELIAC DISEASE AND TYPE 1 DIABETES  
2.3.1 History 
The coexistence of CD and T1D was first described in 1969 by John A Walker-Smith and 
W Grigor (92). They reported a short case study in a letter to the Editor of The Lancet, 
describing biopsy-proven CD in a girl with newly diagnosed T1D. Previously, Hooft et al 
had published a paper on a series of children with T1D and malabsorption (93), even 
though CD had not been confirmed by biopsies in all of them. More clinicians then started 
submitting case reports on CD in T1D (94-96).  
Over the next three decades, research about these diseases, and the combination of them, 
intensified worldwide (97). From the 1970s onwards, several studies provided support for 
the concept that there was a causal relationship between CD and T1D (97-100).  
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The separate milestones in the history of each disease have provided a better understanding 
of the coexistence of CD and T1D. In the 1980s, HLA was described as a major genetic risk 
factor for CD (49) and this was later complemented by discoveries about sharing risk genes 
and protector genes (101). The genetic background, especially with regard to the HLA 
genes, has been the most well-studied factor in relation to the coexistence of these diseases 
(102).  
In 2007, Lohi et al showed an increased prevalence of CD when the prevalence of T1D 




Figure 8. Increasing 
prevalence in percentage (%) 
of both T1D and CD over 
time.  
Printed with permission from 








The publication of international recommendations about screening all children and 
adolescents with T1D for CD, improved awareness among the medical community (103), 
and may have led to an increased interest in the coexistence of both diseases.  
Studies about the effects on the clinical course of diagnosing CD in children with T1D, 
together with other benefits, have driven the development of more guidelines (104). In 
addition, the clinical responses and benefits of treating CD with a gluten free diet in T1D 
patients had been reported (105, 106).  
The 2004 diabetes clinical guidelines from the National Institute for Health and Clinical 
Excellence (NICE) recommended that individuals with T1D should be screened for CD at the 
time of diagnosis and then at least every three years (107, 108). However, NICE updated its 
guidance in 2009 to state that CD screening should only be performed at the time of T1D 
diagnosis (107, 109). It worth noticing that the latest version of NICE guidelines changed 
again and embraces the ESPGHAN guidelines for CD diagnosis in children (110). 
Furthermore, the 2006-2007 ISPAD Clinical Practice Consensus Guidelines, about other 
complications and conditions associated with diabetes, stated that: “Screening for coeliac 
disease should be carried out at the time of diagnosis and every second year thereafter. 
More frequent assessment is indicated if the clinical situation suggests the possibility of 
coeliac disease or the child has a first-degree relative with coeliac disease” (111). 
 
Increasing prevalence of coeliac disease over time




The latest version of the ISPAD recommendations were published as an update in 2018. 
They include recommendations about CD screening and also emphasise the importance of 
nutritional support if CD is diagnosed (112). 
The 2012 ESPGHAN guidelines supported CD screening for patients with T1D, as well as 
for other conditions associated with CD (3). The 2020 ESPGHAN guidelines state that 
children with T1D could not be included in the no biopsy approach to CD diagnosis, due to 
lack of published data. However, they do encourage high-quality studies on children 
without symptoms, particularly those with T1D (22). 
 
2.3.3 The case for screening 
In modern medicine, principles of beneficence and ethical decisions based in evidence have 
been prioritized. To screen for a disease within these principles need to comprehend the 
same ethical criteria. The World Health Organization (WHO) criteria for screening from 
1968 (113) fits well for the case of screening CD in patients with T1D (114).  
The CD screening procedure that is common in clinical practice (115)follows the simplified 
algorithm showed in Figure 9.  
 
 
Figure 9. Simplified algorithm for diagnosing CD by screening children and adolescents 
with T1D.  
1. Children and adolescents diagnosed with CD before their T1D diagnosis do not need to 
be screened.  
2. The CD screening should include tTG antibodies, possible other biomarkers and a 
genetic HLA test. 
3. If the CD biomarkers are negative, the screening should be repeated later. How often, 
and after how long, has not been decided. 
4. If the CD biomarkers are positive, the child should be referred for an endoscopy to 
retrieve biopsies.  
5. If the biopsy results are normal, the screening should be repeated later. How often, and 
after how long, has not been decided. 
















2.3.4 Screening prevalence  
The prevalence of CD in T1D varies in different parts of the world. Though, results about 
biopsy proven CD in T1D are not yet available from all countries. In Figure 10, the 
prevalence of CD in different child populations with T1D diagnosis is presented. 
In Sweden, the first study on the prevalence of CD in children with T1D showed that it was 
21/459 (4.6%) (116). The next study, in 1999, showed a prevalence of 9/115 (7.8%) (117). 
Almost 10 years later, in 2008, a study was published that showed a prevalence of 29/300 




Figure 10. Prevalence 
figures of the  
co-occurrence of CD  
and T1D in children  
and adolescents. 
Adapted from Kaur et al 
(120) and modified with 
information from 











2.3.5 Immunological pathogenesis 
Both CD and T1D have common features, including certain genetic risk factors and 
underlying mechanisms. Multiple triggers that start the immunological reaction that leads to 
the autoimmune response have been suggested (102). Similarities and differences about the 
knowledge on the pathogenesis of both diseases can be seen in Figure 11.  
Coeliac Disease  Type 1 Diabetes 
 
 
Figure 11. Model of common features of immunological pathogenesis in T1D and CD. 
Verdu et al state that: “In CD, bacterial or viral pathogens might alter the innate immune 
response or the gluten-specific T cell response, both of which are critical events for the full 
development of disease. In T1D, microbial products, viral infections, dietary practices and 
alterations in microbial structure and function have been suggested to be triggers of 
disease, but the mechanisms are less well understood.” 
Printed with permission from the publisher (48). 
 
2.3.6 Multifactorial aetiology 
CD and T1D share genetics and may also share some environmental trigger factors (102). 
Gluten is the major trigger for CD and it has been suggested that it also plays a role in T1D, 
even if the possible mechanism that triggers T1D autoimmunity is not known (120). 
Perinatal risk factors may also affect the risk of the co-occurrence of T1D and CD (124).  
In addition, viral infections and disturbances in the gut microbiome and mucosal barrier 
function have been suggested as triggering factors (48), while early infections may have 
protecting effect (125) (Figure 11).  
In the past decade, interesting prospective birth cohorts and population-based studies of 
populations at-risk for T1D and CD have begun. The results from these studies may help to 
identify common environmental risk factors and their mechanisms of action (48). 
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2.4 KNOWLEDGE GAP 
When the first study in this thesis was designed, paediatric endocrinologists frequently 
expressed concerns about giving a second diagnosis to children and adolescents who had 
already been told they had T1D. In fact, the frequency of screening for CD in children and 
adolescents with T1D had been reported to be low (103). At the same time, our knowledge 
had increased about the potentially avoidable health consequences of undiagnosed CD (126-
128). 
Paediatric gastroenterologists in Stockholm were seeing many children and adolescents with 
T1D, but they were also noticing some delays in referrals for endoscopies and biopsies. We 
wanted to determine the real prevalence of CD at our clinic and to identify the difficulties in 
the procedure that children and adolescents with T1D were screened for CD. At that time, 
only a few studies had examined the prevalence of CD in Swedish children and adolescents 
with T1D (116, 117) and none of those studies had been conducted in Stockholm.  
The Swedish CD epidemic had been thoroughly described by several studies (12, 18, 19, 129) 
before Study I, but no information had been published about the high-risk population of 
children and adolescents with T1D. When the results from Study I were published, they 
indicated that the CD epidemic had little effect on the prevalence of CD in birth cohorts with 
T1D in Stockholm. However, it was still unclear whether these results could be generalised to 
the whole paediatric population with T1D, which led to Study II.  
Genetic factors shared by CD and T1D were already well known (130). However, the 
association between the CD biomarker tTG and diabetes autoantibodies, at the onset of T1D, 
had not been thoroughly explored. Therefore, this was the focus of  Study III.  
In 2012, ESPGHAN published new guidelines with different logarithms for diagnosing CD, 
included a specific algorithm that made a no biopsy approach possible in certain cases (3). 
However, children and adolescents with T1D were not included due to lack of data on 
asymptomatic children, and on children and adolescents with T1D (3).  
Over the following years, several studies explored if the 2012 ESPGHAN guidelines could be 
applied to screened and/or asymptomatic children (37-42). Despite this, very few studies 
focused on children and adolescents with T1D (131). Therefore, when the latest 2020 
ESPGHAN guidelines were published, they stated that children and adolescents with T1D 
were still excluded, due to the lack of data on the T1D population (22). This lack of 
information was addressed in Study IV, we wanted to explore whether it was safe to diagnose 
CD in children and adolescents with T1D without an invasive biopsy. That is why Study IV 
explored the CD biomarker tTG levels that would be needed to justify the no biopsy approach 
in children and adolescents with T1D. 
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3 AIMS AND HYPOTHESIS OF THE THESIS 
The overall aim of this thesis was to expand current knowledge about CD in children and 
adolescents with T1D.  
The specific aims were as follows: 
• To investigate the prevalence of CD in children and adolescents with T1D, in 
Stockholm (Study I) and Sweden (Study II).  
• To explore the prevalence of CD in children born during the Swedish CD epidemic, 
by comparing those born before (Study I) and after the epidemic (Studies I and II).  
• To examine the association between HLA genotypes and the CD biomarker tTG 
levels and autoimmunity biomarkers for T1D in children and adolescents newly 
diagnosed with T1D (Study III).  
• To show if it would be safe to diagnose CD without an invasive biopsy in children 
and adolescents with T1D, and, if that was the case, in what circumstances and with 
what level of CD biomarkers (Study IV).  
• To assess whether the screening procedure for diagnosing CD in children and 
adolescents with T1D could be improved (Studies I, III, and IV). 
The main hypotheses were as follows:  
The main hypothesis for Study I was that the prevalence of CD in Stockholm in children and 
adolescents with T1D would be high in comparison to European countries. Another initial 
hypothesis was that the children with T1D would have a higher prevalence of CD during the 
Swedish CD epidemic, as the rest of the Swedish child population. A secondary hypothesis 
was that the number of adolescents lost to follow up would be high and the delay in referring 
children and adolescents for a CD diagnosis would be too long. 
However, as the hypothesis about high prevalence during the Swedish CD epidemic was 
refuted in Study I, the hypothesis for Study II was that children and adolescents with T1D 
would not follow the same pattern as the general population and would have a similar 
prevalence of CD in birth cohorts born during and after the Swedish CD epidemic. 
In Study III, the main hypothesis was that the CD biomarker tTG levels would be related to 
the HLA genotype, but not to the diabetes autoantibodies, IAA, GADA, IA-2A or ZnT8A, in 
children and adolescents with newly diagnosed T1D. 
In Study IV, the hypothesis was that high levels of tTG, as a CD biomarker in peripheral 
blood, would be a reliably way to give CD diagnosis in children and adolescents with T1D, as 
in other screened or asymptomatic children. The hypothesis regarding improvement of 
screening procedure was that at least two-thirds of the children with T1D and with suspicious 








5 RESEARCH APPROACHES 
5.1 STUDY POPULATIONS 
All studies included in this thesis were based on Swedish cohorts. Sweden is a Scandinavian 
country and its population was 10,358,538 in July 2020, compared with 8,590,630 in 
December 1990. Although the population has grown in the last 30 years, the number of 
children under 18 has been stable, with small fluctuations (132) (Figure 12). 
 
 
Figure 12. Population in Sweden, showing a stable proportion of individuals under 18 
years of age (132).  
 
During the study periods covered by this thesis, all Swedish children with diabetes attended 
paediatric diabetes clinics in their local hospitals, at diagnosis and for follow-up 
appointments. All outpatient evaluations, hospital admissions and prescribed drugs were free 
of charge for patients up to the age of 18. In addition, gluten free products were subsidised for 
children and adolescents diagnosed with CD, but the upper age limit depended on which 
region they lived in. 
The children and adolescents studied in this thesis were born between 1981 and 2010. The 
different study birth cohorts are presented in the lower panel of Figure 13, on the next page, 
and this follows the graphs of the incidence of T1D and CD in the general childhood 
population. 
 
5.2 STOCKHOLM COHORT 
Study I was performed in Stockholm, the capital of Sweden, by researchers based in the 
Karolinska University Hospital. The hospital covered the central and north of the city: there 
were around 250,000 children up to the age of 18 years in 1995 and around 275,000 in 2004. 
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Figure 13. Incidence of T1D (upper panel) and CD (middle panel) in Swedish children, 
according to age, and a timeline of the birth cohorts in Studies I-IV (lower panel).  
Notice the two different scales in the X-axes in the upper and middle panel.  
Graphs printed with kindly permission from Berhan et al and the publisher (73), and 
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Comparison of the T1D and CD 
incidence trends in the study cohorts
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All children with T1D from birth to 17.9 years of age, who attended the paediatric diabetes 
clinic at St Göran Children’s Hospital (1995-1997) and Astrid Lindgren Children’s Hospital, 
a part of Karolinska (1998-2004), were registered in the DiaBase diabetes database. The 
WHO criteria for diagnosing diabetes were used (133), and 1,151 children in the DiaBase 
database from 1995 until 2004 were included in the retrospective analysis in Stockholm. The 
study cohort consisted of 847/1,151 of those subjects. Eight children had known CD before 
their diagnosis of T1D, three children underwent biopsy before screening due to symptoms 
and 836 children were screened. For comparison, we constructed three birth cohorts based on 
the years of the Swedish CD epidemic (18): before the epidemic (1984-1996), during the 
epidemic (1981-1983) and after the epidemic (1997-2004). 
 
5.3 SWEDISH REGISTRIES 
The Government-administered health registries in Sweden are the National Board of Health 
and Welfare. The information that they obtain incudes hospital-based inpatient and outpatient 
care (134).  
Swedish Healthcare Quality Registries collect individual-based detailed clinical data, and 
provide an important source of information about specific diseases (135). 
In Study II, children diagnosed with both T1D and CD were identified by merging 
information from Statistics Sweden and five national registries:  
Statistics Sweden 
Two birth cohorts from the general population were included in Study II: one cohort born in 
1992-1993, during the Swedish CD epidemic and the other cohort born in the post-epidemic 
era of 1997-1998. Data on the population, sex, immigration and mortality were collected 
from Statistics Sweden. 
Swedish inpatient, outpatient and day surgery registries 
The inpatient, outpatient and the day surgery registries, which also are part of the National 
Board of Health and Welfare Register, were used to extract diagnostic data. The date when 
T1D was diagnosed was recorded, as well as the first visit with a CD diagnosis. The coverage 
and PPV for different diagnoses in these registries was assessed over time by an external 
review and validation study that showed that the included data were of a high standard (134). 
Swediabkids and the National Diabetes Register 
The disease specific Swedish Healthcare Quality Register Swediabkids, which covers 
patients below 18 years of age with diabetes, is a part of the National Diabetes Register 
(NDR) and provides a high coverage of individuals with T1D. The NDR was established in 
1996 and Swediabkids started in 2000. Swediabkids comprises more that 7,000 children, 
and is nearly 100% complete (135). 
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5.4 BETTER DIABETES DIAGNOSIS STUDY 
The BBD study is an ongoing nationwide prospective study with the aim to improve the 
knowledge of diabetes in Swedish children under the age of 18. The main aim of the study 
is to develop a more precise classification and diagnosis of diabetes, so that clinicians can 
provide the best treatment for each patient, and to increase knowledge on the underlying 
factors behind diabetes. The secondary aims include exploring co-morbidities and risk 
factors for late complications (136). 
The study started in May 2005 and since then data on almost all children and adolescents 
with newly diagnosed diabetes in Sweden have been prospectively collected, including 
genetic analyses and autoantibody detection (136). 
The American Diabetes Association criteria for classifying T1D have been used to 
determine the clinical diagnosis of diabetes in the BBD study (69). Furthermore, the 
diabetes diagnoses were re-evaluated after one year. All of the children who were included 
in Studies III and IV met the criteria for T1D. 
The Study III cohort was a sub-study of 2,705 children and adolescents with T1D. They 
were subsequently recruited between May 2005 and November 2009, from 40/42 (95%) of 
the Swedish paediatric diabetes clinics. 
Study IV included 2,035 children with T1D, recruited between May 2005 and December 
2010, who were selected from 13 of the paediatric diabetes clinics. These centres collected 
results of anti-tTG and intestinal biopsies from patients investigated for CD. The 13 clinics 
that were involved in the study were: Göteborg, Helsingborg, Jönköping, Kristianstad, 
Linköping, Lund, Malmö, Norrköping, Stockholm, Västerås, Ystad, Örebro and Östersund.  
 
5.5 COELIAC DISEASE BIOMARKERS 
Several serological tests were used as CD biomarkers in Study I. IgA gliadin antibodies 
(AGA) were measured using an enzyme-linked immunosorbent assay (ELISA). The cut-off 
for AGA was <50 U/mL. In addition, IgA endomysial antibodies (EMA) were analysed 
using an immunofluorescence in-house technique with monkey oesophagus as the antigenic 
substrate. The cut-off titre for EMA was dilutions under 1:10. Last, but not least, IgA tTG 
were determined by ELISA (Binding Site, West Midlands, UK). The tTG cut-off was <4 
U/mL (137). Prior to 2002, serological screening involved AGA and EMA. After 2002, tTG 
replaced EMA and AGA was analysed as a complementary test for children younger than 
two years of age. Furthermore, total IgA was checked to rule out IgA deficiency in all 
samples. When total IgA deficiency was found, the patients were tested with IgG 
endomysial antibodies. 
The CD biomarker used in Study III was tTG. The tTG levels (kit No. L2KTD6) were 
analysed from serum samples on the Immulite 2000 analyser (Siemens Healthcare 
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Diagnostics, Deerfield, IL, USA), according to the manufacturer’s instructions. Values > 50 
IU were considered positive and values between 10 and 50 were considered borderline. In 
addition, the values were evenly distributed and there were no clusters of values. 
Two different assays were used to analyse tTG levels in Study IV. Both assays were 
provided by Thermo Fisher Scientific systems (Legal Manufacture Phadia AB, Uppsala, 
Sweden). One was an enzyme-linked immuno-assay (EliA), the EliA Celikey IgA, with the 
level of positivity set at >10 U/mL. The other was an ELISA, the Celikey Tissue 
transglutaminase IgA Antibody Assay, with the level of positivity set at >8 U/mL. All 
children were screened for CD using anti-tTG when their diabetes was diagnosed and then 
at yearly intervals as part of the clinical routine. The autoantibody levels were grouped 
according to the last positive value before each patient’s biopsy. Furthermore, total 
immunoglobulin A was tested to rule out immunodeficiency that would not detect anti-tTG 
of this type. Children with IgA deficiency were excluded in this study. 
 
5.6 HLA TYPING 
The HLA profile was analysed for all children included in the BDD study and the data were 
used in Studies III and IV. Blood samples were obtained at the clinical diagnosis of T1D 
and further processed by the Clinical Research Centre at Malmö, which is a part of Skåne 
University Hospital. HLA genotypes were analysed by sequence-specific oligonucleotide 
probes on dried blood spots and used directly for polymerase chain reaction amplification, 
as previously described (136, 138), using a DELFIA hybridization assay (PerkinElmer Inc., 
Waltham, Massachusetts, USA). 
For comparison purposes, HLA genotyping were classified into four groups of genotypes, 
annotated with the short term nomenclature (50, 139): (i) DQ2/2, DQ2/X, and DQ2.2/X;  
(ii) DQ2/8; (iii) DQ8/8 and DQ8/X and (iv) DQX/X, where DQX was any haplotype other 
than DQ2, DQ2.2 and DQ8. 
 
5.7 BIOPSIES 
In Studies I and IV, the parents of the patients with positive serology were advised to let 
them have small intestine biopsies. The biopsies were obtained according to local clinical 
routines, mostly by endoscopy and sometimes by suction capsule. They were further 
assessed by local pathologists. In Study I, the examinations at the Department of Pathology, 
Karolinska University Hospital, were mainly performed by two pathologists. In Study IV, 
biopsies were assessed by the pathology departments of the different clinics. Further, in 
Study IV, the histological results were reviewed and scored by the same person, according 
to the revised Marsh-Oberhüber classification (26, 27) (Figure 3, page 8). In this context, it 
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is worth mentioning that biopsy evaluations from all the pathology departments in Sweden 
had been evaluated and had shown a high concordance with CD diagnoses (140).  
 
5.8 STUDY DESIGN REGARDING SCREENING AND DIAGNOSIS 
We have provided simplified schematic figures for each of the study designs. These show 
the screening procedure and the way we diagnosed CD in children and adolescents with 
T1D in the studies included in this thesis. 
The majority of the children in Study I were screened for CD. There were also a small 
number who had already been diagnosed with CD and were not screened. One limitation of 
the study design was adolescents lost to follow up and diagnostic delays (Figure 14). 
Figure 14. Simplified algorithm for diagnosing CD by screening children and adolescents 
with T1D in Study I.  
 
Study II was a database cohort study in which two different birth cohorts were assessed and 






Figure 15. Simplified algorithm 
for diagnosing CD in children 
and adolescents with T1D in 





In Study III, the endpoint was to assess CD autoimmunity and the value of HLA typing. 
T1D autoantibodies were also evaluated. In this study we did not have information about 
the children with known CD (Figure 16). 
 




Study IV comprised children with known CD before their T1D diagnosis. We assessed 
HLA typing and the levels of tTG autoantibodies compared with the mucosal damage seen 
in the biopsies (Figure 17). 
 
Figure 17. Simplified algorithm for diagnosing CD by screening children and adolescents 
with T1D in Study IV.  
 
 
Abbreviations in the algorithms: 
CD, coeliac disease 
T1D, type 1 diabetes 
tTGA, tissue transglutaminase antibodies IgA 




5.9 DIABETES AUTOANTIBODIES 
GADA, IA-2, and IAA 
Recombinant GADA and IA-2 were labelled with 35S-methionine (GE Healthcare Life 
Sciences, Amersham, UK) by in vitro coupled transcription and translation in the TNT SP6 
coupled reticulocyte lysate system (Promega, Southampton, UK) as previously described 
(141). IAA were determined in a non-competitive radioligand-binding assay using 125I-
insulin, as previously described (142). Details of the procedures, the intra-assay coefficients 
of the variations and the validation of the laboratory have previously been described (81). 
Samples were considered positive if GADA was > 50 U/mL, IA-2A was > 10 U/mL and 
IAA was > 1 RU. Furthermore, values for GADA of 35-50 U/mL, IA-2A of 6-10 U/mL and 
IAA between 0.81-1.0 RU were considered borderline. 
Autoantibodies to Zinc transporter variants 
The radioligand-binding assay for all three ZnT8A variants (ZnT8R, ZnT8W and ZnT8Q) 
were performed separately, as previously described (143), and the intra-assay coefficients 
of the variations and the results of the laboratory validation have also been previously 
described (81). The cut-off values for ZnT8RA were ≥75 U/mL, for ZnT8WA they were 
≥75 U/mL and for ZnT8QA they were ≥100 U/mL to positive. Furthermore, values 
between 60-74 U/mL for ZnT8RA, 60-74 U/mL for ZnT8WA and between 70-99 U/mL for 
ZnT8QA were considered borderline. 
 
5.10 STATISTICAL METHODS 
Microsoft Excel and Microsoft Access were used for data handling (Microsoft Corp, 
Washington, USA). The data analysis was carried out using SAS system for Windows, 
version 9.1 (SAS Institute Inc, Cary, NC, USA) in Studies I and III, and SPSS software, 
version 25 (IBM Corp, New York, USA) was used in Studies II and IV.  
The quantitative variables have been expressed as ranges, medians, means and standard 
deviations of the mean and the categorical variables have been described as frequencies 
and/or percentages.  
All tests based on proportions were carried out using the test of homogeneity, based on the 
chi-square distribution or, in the case of small expected frequencies, Fisher’s exact test. 
Comparisons between the three birth cohorts in Study I were carried out using analysis of 
variance, followed by a post-hoc test. The procedure proposed by Fisher was used to 
control for multiplicity.  
The scatter plot in Study IV was created using GraphPad Prism 7.0 (GraphPad Software, 
California, USA).  
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In all studies, the 5% level of significance was considered. If there was a statistically 
significant result, the probability value (p-value) was given. When appropriate, the 95% 
confidence interval (CI) was presented. 
 
5.11 ETHICAL APPROVAL 
When we were planning the study designs for the papers in this thesis, there were six 
Regional Ethics Review Boards in Sweden under the Ministry of Education, which were 
located in Gothenburg, Linköping, Lund, Umeå, Uppsala and Stockholm. Today, since 
2019, one central Ethics Review Authority archives all previous review requests.  
The Regional Ethics Review Board in Stockholm approved Study I (registration number 
2007/588-31/4). In addition, the BDD study was approved from the same regional board 
(2004/826/1) with amendments (2006/108-32/1, 2007/1383-32/1, 2009/1684/32 and 
2011/1069/32), which regards Study III and the first part of Study IV. 
The Regional Ethics Review Board in Lund approved Study II and the second part of Study 
IV (2014/476). 
 
5.12 ETHICAL CONSIDERATIONS 
All the studies were performed according to good practice for clinical investigations, based 
on the Declaration of Helsinki. The Declaration has been amended seven times since it was 
first published in1964 and the latest amendment was in 2013 (144). 
Study I was a retrospective study and this meant that the children and adolescents and their 
families, could not be asked for written consent before reviewing their medical records. The 
Regional Ethics Review Board in Stockholm gave us permission to proceed with the study, 
because the knowledge we produced could benefit the study population, as one of the aims 
was to improve the screening procedures at the local paediatric diabetes clinic in North 
Stockholm. 
Study II was based on medical data from different population-based registries and disease-
specific Swedish healthcare quality registries. The National Board of Health and Welfare 
collects health information that does not require consent and it only provides data for 
studies that have received ethical approval. All the data were anonymized before we 
received it to protect patient privacy.  
Studies III and IV were based on the same ongoing national prospective study, the BDD 
study (136). All the parents and capable children gave their informed, written consent to 
participate in the BDD study before inclusion. They were informed about the study design 
and the purpose of the study. In addition, they were informed that they could withdraw 
from the study at any time without any effect on their future treatment or care. 
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Furthermore, in Study III and IV, all the information about the HLA and autoantibody 
results was reported to the patient’s local diabetes clinic. This directly benefitted the 
children who participated, as the information allowed clinicians to reach a more precise 
classification of their type of diabetes and assess their risk for co-morbidities, such as CD. 
The local paediatric diabetes clinic was then responsible for following up the patients.  
In Study IV, we aimed to study if it was appropriate to diagnose CD in patients with T1D 
without a biopsy. A sub-population of children participating in the BDD study was selected 
and we collected follow-up information about the risk for CD, the development of CD 
biomarkers and the biopsy results. A separate ethical application for this part of the study 
was approved to retrieve data from the patients’ medical records. The children that had 
already been diagnosed with CD will not benefit directly from the results of Study IV, but 
we hope the results will benefit children and adolescents with T1D towards a diagnosis of 
CD in the future. 
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6 RESULTS AND DISCUSSION 
6.1 PREVALENCE OF COELIAC DISEASE IN CHILDREN AND 
ADOLESCENTS WITH TYPE 1 DIABETES 
The prevalence of CD in children with T1D was calculated in three of the studies included in 
this thesis: Studies I, II and IV. CD autoimmunity was calculated as a proxy for CD in Study 
III. 
Study I confirmed a high prevalence of CD in Swedish children and adolescents with T1D. 





Figure 18. Flowchart of Study I.  
Printed with permission from the publisher (Study I). 
 
The prevalence of CD in children and adolescents with T1D reported in Study I was higher 
than some previous Swedish studies (116, 117), but similar to others (118, 119). The 1999 
paper by Carlsson et al (117) reported findings of an observational study that was performed 
in a tertiary hospital in Malmö, southern Sweden. The selection bias seen in that study, due 
to loss to follow up, was also a concern in our study when it came to the outcomes. The 
differences in CD prevalence between the studies in the 1990s and our higher prevalence in 
Study I, may be due to the study design, but a real increase in CD prevalence in the T1D 
population during this time cannot be excluded. 
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Study I confirmed similar high prevalence than in other parts of the country. Our results were 
similar to the findings in one study performed in Skåne, a province in southern Sweden (118), 
with a prevalence of CD of 29/300 (9.7%; 95% CI 6.6-13.6). In our Stockholm study the 
prevalence was slightly lower, but with a smaller 95% CI due to the larger T1D population 
that was screened. Nevertheless, the results showed to be very close, and these two studies 
used similar age range and birth cohorts, and may have some comparable limitations. In 
addition, confirming our results, a later study from Uppsala, a city situated north of 
Stockholm, showed a prevalence of CD slightly higher, 17/169 (10.1%), and within similar 
95% CI (119).  
Furthermore, the prevalence of CD found in Stockholm in children with T1D can be 
considered to be high worldwide (Figure 10). It was higher than many European studies and 
studies from Australia and North America (40, 122, 123). Whereas, at the same level as some 
other Scandinavian studies (105, 145), as well as studies from Libya (146), India (147) and in 
Saudi Arabia (148). However, not as high as the highest reported from a smaller study, with a 
CD prevalence of 19/116 (16.4%) in West Algeria (149). This variety in prevalence may be 
due to differences in study design and time of follow up, but the HLA-upset in the different 
diabetes populations may also have an impact of the prevalence of CD. 
The strength of Study I was the possibility to study a screening procedure in a clinical setting, 
and also an inclusion of all the children with T1D in the North Stockholm area over a long 
period of time. In addition, the timeframe included birth cohorts before, during and after the 
Swedish CD epidemic. This provided us with the unique opportunity to study children with 
high-risk of CD in different circumstances.  
One limitation of Study I, was the possible selection bias due to loss of follow up of some 
adolescents. We identified, on one hand, 15 children and adolescents that were very likely to 
have CD due to repeated high CD biomarkers, but were not referred for a biopsy procedure 
during childhood and, on the other hand, 304/1,151 individuals (26.4%) that were never 
screened during childhood. Even taking this into account, and assuming that no more cases of 
CD would have been found in these individuals, the prevalence of CD would still be high.  
Similarly, the results from Study II confirmed that the national prevalence of CD was very 
high. The overall prevalence of CD in children and adolescents with T1D was 337/3,022 
(11.1%; 95% CI 10.1-12.3). The two different birth cohorts that were created covered the 
period of the Swedish CD epidemic and one that covered the post-epidemic period. The 
prevalence od CD for the epidemic cohort was 176/1,642 (10.6%; 95% CI 9.2-12.2). This 
prevalence was not statistically different to the one showed in the post-epidemic cohort,1997-




             
 
Figure 19. Flowchart of study II. Selection of individuals diagnosed with T1D under the 
age of 17 years, one cohort born during the Swedish CD epidemic (1992-1993) and one 
born after the epidemic (1997-1998).  
 
In addition, the prevalence of CD in study IV was high, but not as high as in Studies I and II. 
(Figure 20).  
                
Figure 20. Flowchart of study IV. The process for diagnosing CD in children with T1D 
with antibodies against tissue-transglutaminase (anti-tTG) and biopsies. The levels of tTG 
are presented as up to 10 times the upper limit of normal (<10x ULN) and at least 10 times 
this limit (≥10x ULN). 


































anti-tTG ≥10 ULN 
n=60
All 60 confirmed CD
anti-tTG <10 ULN
n=59
Confirmed CD n=53 
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Study IV was based on tTG IgA type. Positive tTG was found in 141/2,003 (6.9%) of the 
screened children with T1D, whereas CD was diagnosed in 113/2,003 (5.6%) of the screened 
children during the follow-up period, which ranged from eight to13 years from the diagnosis 
of T1D. When we added the 32 children who had been diagnosed with CD before T1D, the 
overall prevalence was 145/2,035 (7.0%; 95% CI 6.0-8.2). 
Even though the overall prevalence of CD, seen in Figure 20, was high, it may have been 
underestimated due to the study design. There was some selection bias, as children with IgA 
deficiency were indirectly excluded because of the method that was used. A further 22 
children were excluded: the parents of 21 children did not want them to have an endoscopy to 
obtain biopsies and one child had an inconclusive biopsy.  
With regard to Study III, even when CD autoimmunity was the endpoint, the presence of tTG 
at the time of the T1D diagnosis was high at 148/2,705 (5.4%). These results about CD 
autoimmunity may suggest a high prevalence of CD already at T1D diagnosis (Figure 21). 
                   
 
Figure 21. Flowchart of Study III: the BDD study and tTG IgA type (here abbreviated 
tTGA) in children and adolescents newly diagnosed with T1D.  
Printed with permission from the publisher (Study III). 
 
This 5.4% level of CD autoimmunity was also considered a high level for the first screening 
of CD in children and adolescents with T1D. However, we are aware that the prevalence of 
CD at the time of a T1D diagnosis could not only be based on CD autoimmunity and, 
furthermore, we did not have data on which children had CD diagnosed before they were 
diagnosed with T1D. 
The results presented in this thesis, especially the early preliminary results from the first 
study, had an impact on how the Swedish endocrinology paediatric community followed the 
screening recommendations. When the first preliminary results from Study I were presented 
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to colleagues at our clinic in Stockholm, there were no national guidelines or international 
consensus about how often to screen children with T1D or for what period of time following 
their T1D diagnosis. Even when the local guidelines were in place at our Stockholm clinic, 
the recommendations were not always followed.  
Several arguments have been used to validate repeated serological tests. That is maybe why 
endoscopies and biopsies have been postponed which have delayed the diagnoses of CD in 
children with T1D. One reason for this could have been some misconceptions about the need 
to start a gluten-free diet when children screened positive for CD. Another concern could 
have been the concept that the presence of tTG at the time of T1D diagnosis, was only a part 
of a general autoimmune reaction, and they would therefore disappear later. In addition to 
this, the guidelines from ISPAD did not recommended CD screening until 2007 (111). The 
findings from Study I helped convince the paediatric diabetologists in our clinic about the 
importance of following the local recommendations.  
By the time the results from Study I were presented, the guidelines did not specify how often 
children with T1D should be screened for CD or for how long the screening should continue. 
Furthermore, not all other guidelines followed ISPAD’s lead and recommended that T1D 
patients were screened for CD (150). In addition, the ESPGHAN guidelines from 2012 
recommend retesting at-risk children at intervals, but with no firm evidence of frequency (3), 
and the 2020 ESPGHAN guidelines had no additive information about it (22).  
 
6.2 THE SWEDISH EPIDEMIC OF COELIAC DISEASE IN TYPE 1 DIABETES 
Studies I and II assessed the de novo knowledge about children and adolescents with T1D 
who developed CD in unique, paediatric Swedish populations before (only Study I), during 
and after the country’s coeliac epidemic.  
The aim of Study I was to assess the overall prevalence of CD in children and adolescents 
with T1D in Stockholm, as well as to determinate the prevalence of CD in birth cohorts 
before, during and after the Swedish CD epidemic. There were some epidemiological 
restrictions with regard to the birth cohorts born in Stockholm in 1981-1983 (pre-epidemic), 
1984-1996 (during epidemic) and 1997-2004 (post-epidemic), such as the screening 
frequency and duration. However, there were no statistically significant differences in the 
prevalence of CD in these cohorts (Table 3).  
Table 3. CD in children and adolescents with T1D in relation to the Swedish CD epidemic. 
The prevalence in each year range is presented as the percentage and 95% CI.  




Number of CD cases 
before screening
Number of CD cases 
found by screening
Total number of CD 
cases
Mean CD cases per 
year of birth
Number of screened 
children
Prevalence in each cohort 
(%) (95 % CI)
1981-1983 2 3 5 1.67 126 3.9 (0.6-7.3)
1984-1996 8 52 60 4.62 630 9.4 (7.1-11.7)
 1997-2004 1 11 12 1.5 80 14.8 (7.1-22.5)
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One noticeable limitation with regard to the external validation of the results in Study I was 
the imbalance in the number of screened children with T1D between the birth cohorts. 
Another limitation was the follow-up period, which was especially short in the children born 
after the epidemic and even shorter in the children born during the new Millennium.  
Importantly, the results in Study I encouraged us to explore the prevalence of CD in 
paediatric patients with T1D at a national level. Study II was designed to identify the 
prevalence of CD in T1D patients in two separate birth cohorts, one born during the epidemic 
and one born post-epidemic. However, the assessments of the 1981-1983 pre-epidemic 
cohorts were not included. This was because the national data about people born in the 1980s 
was considered less reliable than later records.  
The prevalence of CD in these birth cohorts during and after the epidemic was similar and 
confirmed the findings of Study I: 176/1,642 (10.7%; 95 % CI 9.2-12.2) individuals with 
T1D born 1992-1993 were diagnosed with CD during childhood, compared to 161/1,380 
(11.7%; 95% CI 10.0-13.5) individuals with T1D born in 1997-1998 (Figure 19). These two-
year periods were chosen from the 1984-1996 epidemic and 1997-2004 post-epidemic birth 
cohorts, to be representative and to give an appropriate power, with a total target population 
of 240,844 individuals born in 1992-1993 and 179,530 individuals born in 1997-1998. 
The main strength of Study II lay in its design, as it was a national assessment of the whole 
population of individuals with T1D in two birth cohorts, one during the epidemic and one 
post-epidemic, which were comparable in size and follow-up periods. The diagnosis of both 
T1D and CD during childhood was assessed in an identical way, which minimised the risk of 
selection bias, and possible regional differences could not affect the general results.  
It would be unethical to replicate the environmental changes that took place during the 
Swedish CD epidemic. Therefore, to being able to study this natural occurrence by using 
various data sources provided us with a unique opportunity. It may be argued that databases 
are not always complete, but to our knowledge the Swediabkids register within the NDR have 
been reported to have achieved almost 100% coverage of all children diagnosed with 
diabetes. Moreover, the NPR has been validated and this showed a very high PPV for CD 
diagnosis from 2001 (134).  
One possible limitation of Study II was that we did not register breastfeeding information or 
whether the parents did, or did not, follow the current feeding recommendations for gluten 
when the study was carried out. Another possible concern was the potential bias of 
misclassified diagnoses. We restricted the cohort to T1D, by checking for a T1D diagnosis in 
the Swediabkids and NDR. The children and adolescents diagnosed with another type of 
diabetes than T1D in Swediabkids, including maturity onset diabetes of the young and 
secondary diabetes, were not included, even if they had a T1D diagnosis in the NPR, because 
not all different types of diabetes have an individual classification in this register as it is in 
Swediabkids. This suggested that we did not have a significant misclassification bias for 
diabetes. In contrast, due to the study design, misclassification of CD diagnoses may have 
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occurred, because we did not have the chance to evaluate the results of biopsies or serology 
tests. However, the accuracy of CD cases that have been diagnosed by biopsies has been 
validated by Ludvigsson et al, with regard to all pathology centres in Sweden (140). 
Furthermore, the overall CD prevalence, was in the same range as in the study from southern 
Sweden (118), from Upsala (119) and Study I, pointing towards a good accuracy of the 
results.  
To summarise, the results produced by Studies I and II about the CD prevalence rates during 
the Swedish CD epidemic indicated that children with T1D, who have a high risk of 
developing CD, were not affected by changes in environmental factors in the same way as 
these changes affected the general paediatric population.  
These findings suggest that the genetic importance was superior to the environmental 
changes. Furthermore, they may indicate the need for observational and interventional studies 
to be revaluated and that studies conducted in children and adolescents who have high-risk 
genes for T1D (60, 151-153) may implicate low external validity for the whole paediatric 
population. The same may be true for other at-risk populations for CD (58, 59, 61). As 
Ludvigsson and Lebwohl commented in an editorial (154), it may not be advisable to base 
new paediatric feeding recommendations for CD based on studies that have only focused on a 
specific group of children, such as babies at-risk for T1D. The results of Studies I and II 
support this editorial. They suggest that it may not be wise to have feeding recommendations 
based on a population at-risk for T1D, which is in he line with our findings where the 
population that developed T1D did not appear to be clearly influenced by the environmental 
changes in infant feeding that gave rise to the Swedish CD epidemic in the general 
population. It would be interesting to evaluate if differences in HLA genotypes, and variants 
within a given genotype (155, 156), have different affects in the T1D population. In addition, 
studies that use a similar design to ours could be carried out to see if first-degree relatives of 
individuals with CD had the same prevalence of CD during and after the epidemic. 
 
6.3 HLA GENOTYPES IN RELATION TO BIOMARKERS FOR COELIAC 
DISEASE, DIAGNOSIS OF COELIAC DISEASE AND AUTOIMMUNITY IN 
TYPE 1 DIABETES 
The aim of Study III was to evaluate genetic associations between different HLA genotypes 
and the CD biomarker tTG, as well as T1D islet autoantibodies. The study was based on data 
from the nationwide prospective cohort of newly diagnosed children and adolescents with 
T1D in Sweden, the BDD study. HLA-DQ2 and/or HLA-DQ8 had been shown to be present 
in 92% of the children with T1D in this cohort (80, 81). We wanted to study if positive tTG 
results were associated with a special HLA genotype and if there were any relationship with 
the spectrum of T1D autoantibodies in these patients. We explored tTG levels at the time of 
T1D diagnosis and compared them to the HLA genotype and the T1D autoimmunity markers, 
namely GADA, IA-2A, IAA and the three variants of ZnT8A, all measured at the time of the 
T1D diagnosis.  
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The presence of HLA-DQ2 and/or DQ8 were found in 91% of the patients, whereas around 
40% had the high-risk genotype for T1D, DQ2/DQ8, the rest of the population (8%) had 
other genotypes and 1% were unclassified.  
In Study III, HLA-DQ2/2 was the highest risk genotype when tTG was present, followed by 
DQ2/DQ8 and DQ2 in combination with other HLA haplotypes. However, most children 
with positive tTG had the genotype DQ2/DQ8, but this was also most frequent in the T1D 
population. Our findings agreed with other studies exploring HLA and confirmed CD in 
children with T1D. Our findings that HLA-DQ2/2 was the high-risk genotype also agreed 
with other studies that evaluated the prevalence of CD in high-risk populations (10, 157) 
(Table 4).  
Table 4. The distribution of HLA genotypes in 2,671children with newly diagnosed T1D, 
and the relationship with tTG.  
Printed with permission from the publisher (Study III) 
  
 
n denotes number; % denotes percentage  
Nomenclature (50, 139): 
DQ2 denotes (DQA1*05:01-DQB1*02:01); DQ8 denotes (DQA1*03:01-DQB1*03:02);  
DQ2.2 denotes (DQA1*02:01-DQB1*02:01); DQX is another haplotype that DQ2, DQ2.2 and DQ8  
┼ p-value 0.00001 (DQ2/2, DQ2.2/X and DQ2/8 compare to DQ8/8 and DQ8/X)  
 
The presence of HLA-DQ2 showed a greater statistically significant difference than the other 
haplotypes in this T1D population, including DQ8. Furthermore, we found that the only child 
that did not have HLA-D2.5 or DQ8, had the HLA-DQ2.2 variant, which also confers a risk 
for CD (50, 139, 158).  
To our knowledge, this was the first study to investigate the association between HLA, tTG 
and diabetes autoantibodies at the diagnosis of T1D, including the three variants of ZnT8A. 
HLA tTG tTG tTG tTG
genetic positive borderline values positive and borderline values negative
markers n  (%) n  (%) n  (%) n  (%)
DQ2/2, DQ2/X and DQ2.2/X 
n=503
DQ2/2 10 (5.8) 8 (4.7) 18 (10.5) 154 (89.5)
n=172
DQ2/X 12 (4.2) 8 (2.8) 20 (7.0) 264 (93.0)
n=284








0 (0) 0 (0) 0 (0) 216 (100)
41 (5.2) 22 (2.8) 63 (8.0) 724 (92.0)
22 (4.4) 17 (3.4) 39 (7.8)┼ 464 (92.2)
21 (1.8) 22 (1.9) 43 (3.7)┼ 1,122 (96.3)
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Even though we did not find any association between these T1D autoantibodies, this 
prospective study provided us with a unique possibility to explore if different T1D 
autoantibodies could predict the presence of tTG at T1D diagnosis.  
The major strength of this study was the large, national, population-based cohort, including 
virtually all of the Swedish children and adolescents with newly diagnosed T1D during the 
study period. Another strength was that HLA, autoantibodies and tTG analysis were 
performed by the same laboratory, under the same conditions during this study. The missing 
data on HLA, which was 34/2,704 (1.3%) of the children and adolescents studied, was very 
low compared to other studies in Europe (39) and in USA (159).  
One major concern about Study III was the possibility of transient autoantibodies. Previous 
papers have discussed that low ranges of tTG can revert to normal over time after T1D 
diagnosis. However, the few studies that formed the basis of ongoing discussions did not 
conduct biopsies to rule out CD in all the children with elevated tTG, or classified all these 
children as potential CD, as recommended by the Oslo classification (5). Using a clinical and 
serological follow up, without performing a biopsy in all the children with low tTG, may also 
be a major limitation of the studies that reported transient low tTG (160-163). We welcome 
new studies on the subject about transient or fluctuating tTG, but this matter did not affect 
how we assessed the results in Study III, as the endpoint was to identify differences in the 
autoimmunity load at T1D diagnosis. 
HLA genotyping was also analysed in Study IV. In this study we were able to determine the 
HLA genotype in children and adolescents with T1D, with the endpoint of CD. The most 
frequent genotype was again HLA-DQ2/DQ8 (42.4%) followed by DQ8/DQX (21.1%). The 
highest risk haplotype was DQ2, as in Study III. 
All but one of the investigated children and adolescents with T1D and CD had the HLA high-
risk alleles for CD: HLA-DQ2 and/or -DQ8. The child that did not have those high-risk 
alleles, had Down Syndrome and this patient’s HLA genotype was DQ7/DQ9. Both DQ7 and 
DQ9 have been shown as a risk for CD. DQ7 has been related to be the most frequent HLA 
in the very few CD patients in the general population without DQ2 or DQ8 (164, 165). In 
addition, DQ9 has also been showed to confer a risk for CD (166). 
To summarize the results about HLA, the high-risk HLA genotypes DQ2 and/or DQ8 were 
virtually always present in children and adolescents with T1D and CD autoimmunity or 
diagnosed with CD. These findings suggested that, for the purpose of screening, the role of 
HLA typing is limited, and could be reserved to identify the approximately 8% of the 
children and adolescents with T1D that would not be at-risk for developing CD. These 
individuals could avoid further CD screening. 
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6.4 TISSUE TRANSGLUTAMINASE ANTIBODIES LEVELS AND BIOPSY 
RESULTS 
The most important result of Study IV was that it confirmed that high levels of IgA tTG 
could predict CD in children and adolescents with T1D. When tTG was 10 times above the 
ULN, the mucosal damage in paediatric patients with T1D was predicted with high certainty 
to have CD. Study IV was based on a national longitudinal population-based prospective 
study, including a large cohort of paediatric patients with T1D who were routinely screened 
for CD (Figure 20). These results were similar to the results from longitudinal large studies in 
children screened for CD for various reasons, not just T1D (37, 41, 42).  
It is interesting to note that also tTG levels that were seven times above ULN provided an 
accurate indication for a CD diagnosis. These results disagreed with a recent study from the 
Netherlands (167), which suggested that tTG levels of 11 times ULN and above were 
accurate for CD diagnosis. The major difference between this Dutch study and our Study IV 
was that six different kits were used during the study period in the Netherlands, while we 
only used two kits from the same manufacturer. 
Only a few previous studies have exclusively reported on the implications of the ESPGHAN 
2012 guidelines for children and adolescents with T1D. In addition, we are only aware of one 
study about CD diagnosis in paediatric patients with T1D that discussed the ESPGHAN 2020 
guidelines (167). Table 5 shows a comparison of the methodology and the results of our study 
in comparison with previous studies.   
 
Table 5. Comparison of results from four different studies (columns 2-5) (131, 167-169) 
and our Study IV (column 6) regarding levels of tTG and biopsy proven CD in children and 
adolescents with T1D.  
 
 
Abbreviations: EMA, endomysial autoantibody, ELISA, enzyme-linked immunosorbent assay; EliA, 
enzyme-linked immunoassay, ULN, upper limit of normal, NA not applicable. 
PUBLICATION Popp et al, 2012 Joshi et al, 2019 Puñales et al, 2019 Wesselts et al, 2020 Study IV 
Study design Consecutive cohort, cross-
sectional test
Longitudinal, population-based 
diabetes register, retrospective 
analysis
Random sample, crossectional 
test
Retrospective observation of 
biopsied children
Longitudinal, nationwide 
population-based study, and 
retrospective analysis of 
medical records
Setting Unclear Database serach, one centre Diabetes reference center Multicentre (13 centers) Multicentre (13 centers)
Country Finland &Romania Western Australia Rio grande do Sul, Brazil Netherlands Sweden
T1D population 181 936 881 Unknown 2003
Age 0-18 0-17.9 0-21 0-18.9 0-17.9
Follow-up time NA, median time from T1D 
diagnosis aprox 3.5 years
NA NA NA range from 8-13 years
CD biomarkers tTG and EMA tTG tTG tTG tTG




Six different ELISA 
manufacturers
ELISA, ELiA, both from Thermo 
Fisher Scientific systems, Legal 
Manufacture Phadia AB, 
Uppsala, Sweden
Biopsy evaluation Marsh-Obenhuber Unknown Marsh-Obenhuber Marsh-Obenhuber Marsh-Obenhuber
Number of biopsies 11 66 62 63 119
CD (%) 9 (5.0) 66 (7.1) 49 (5.6) NA, CD confirmed in 52 
children
113 (5.6)
x ULN non specified 11x ULN and above only intermediate and x1 ULN 11x ULN and above 10x ULN and above
Number of proven CD in high-
titre tTG out the number of 
biopsies
7 out of 7 35/35 NA /  only gradients of tTG 
were described
47/50 for above 11x ULN, and 




The main strength of Study IV was the prospective multi-centre data collection, based on the 
longitudinal, population based BDD register. The BDD study register included a large 
number of participants and had very high national coverage (136). As shown in Table 5, the 
number of children that were screened and the number of biopsies that were performed were 
higher than previous studies. The data analysis was retrospective, but the BDD study design 
implicated no considerable selection bias, as we found few exclusions, missing data or loss to 
follow-up.  
Another strength of the study was the association between tTG levels, and the mucosal 
damage observed in the biopsy samples (Figure 22), assessed with only two different 
biomarker tests (ELISA and EliA), from the same manufacturer. A common concern about 
validating tTG is whether the test kits are universally available. The EliA kit, that was one of 
the tests used in our study, is currently universally available and the reported accuracy has 
been very high (170, 171). 
            EliA    ELISA 
         
Figure 22. Degrees of mucosal damage in relation to anti-tTG using the EliA method to the 
left and the ELISA method to the right. The lines represent the median. The levels of anti-
tTG correlated to the degree of mucosal damage.  
Printed with permission from Pediatric Diabetes. 
 
A possible limitation of the study design was that the biopsies were assessed and classified by 
the local pathologists from each clinic and that the answers were then validated according to 
the Marsh-Oberhüber scale by a single non-blinded co-author. However, we based the study 
design on the notion that a previous validation study of biopsies, that covered all of Sweden’s 
28 pathology departments, concluded that it is feasible to identify CD using regional biopsy 
data (140). This validation study also emphasized that the specificity of the CD biopsy results 
was particularly high in biopsies with villous atrophy (140).  
One restriction of Study IV was that we did not particularly account for patients with IgA 
deficiency. Since ELISA and EliA tests are IgA based, all the children were tested for IgA 
deficiency at the time of the screening. If they were reported as IgA deficient, the method 
used to determine a CD diagnosis was different, as the ESPGHAN and the United Kingdom 
guidelines recommend that children with IgA deficiency are always recommended to undergo 





Another concern about autoantibodies would be that we did not test for endomysial 
autoantibodies (EMA). Both the ESPGHAN 2012 (3) and ESPGHAN 2020 guidelines (22) 
recommend EMA as a second test. In the latter, studies on EMA accuracy were summarized 
and showed a higher sensitivity, but a lower specificity than tTG (22). We did not include 
EMA in our study as local measurements were not available in all parts of Sweden. However, 
we checked for EMA levels in a sample of children from the South of Sweden, where the test 
was available, and found a good correlation between tTG levels and EMA results (Table 6). 
 
Table 6. Children that were tested with 
EMA as a second test after positive  
anti-tTG and the correlation with the 
Marsh-Oberhüber classification of 
biopsies. EMA levels were considered 
normal if dilutions were under 1:10 and 
positive in dilutions greater than 1:10. 




These results for tTG and EMA in relation to high tTG levels were consistent with previous 
studies (170, 171). In a recent Spanish study, Donat el al retrospectively examined discordant 
autoantibody results where the tTG and EMA findings were different. They found that only 
three children with T1D with a normal mucosa were EMA negative and had low levels of 
tTG (172). 
Furthermore, a common discussion concerning CD biomarkers in children and adolescents 
with T1D, has been concerns about transients CD autoantibodies. However, as mentioned 
before, there are few studies regarding transient or fluctuating serological autoantibodies in 
the T1D population (160, 163, 173). Rinawi et al concluded that children with “slightly” 
elevated anti-tTG should be followed up when they were on a diet containing gluten (173). 
Importantly, in the study from Waisbourd-Zinman et al, the levels of tTG were statistically 
significant lower in the group of children with normalized tTG levels compare to those with 
CD diagnosed with biopsies (163).  
Nonetheless, Study IV had focused on children with high anti-tTG antibodies, and we could 
not find any study that had reported consistent findings about transient high levels of tTG. 
Moreover, a population with very high markers for CD may be different when compared to 
children with low antibody responses, as suggested by Mubarak et al (174). 
To summarize, we found a good correlation between tTG levels and mucosal damage and 
that tTG that was above 10 times the ULN could predict CD. As we found that 60/119 
children had tTG that was more than 10 times above the ULN, it would be possible to 








1 19 400 3C
2 110 1600 3B
3 114 1600 3C
4 141 400 3A
5 159 1600 3C
6 162 1600 3A
7 >200 1600 3B
8 >200 1600 3B
9 >200 1600 3C
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6.5 REFLECTIONS ON SEX DIFFERENCES  
Overall, we found some differences between females and males in our studies. These 
differences can be due to the interaction between genetic, epigenetic and environmental 
factors, in the influence of sex hormones. The reasons for differences in the prevalence of 
autoimmune diseases in females and males are still mostly unknown (9). The possible 
influence of sex hormones and chromosomes on the function of the innate and adaptive 
immune systems still need to be explore, with regard to the risk of autoimmune diseases in 
general and CD and T1D in particular (9). 
Study I 
The rate of female and male CD patients in the Stockholm study cohort were similar: 38 girls 
and 39 boys with T1D had also been diagnosed with CD. This equal distribution between the 
sexes had been seen in other screening studies (175-177), but not all (118, 178). 
In Study I, six of the eight children diagnosed with CD before T1D were girls. Unfortunately, 
there was not enough power to analyse these differences statistically.  
A possible explanation for the overrepresentation of girls diagnosed with CD before T1D 
could be that girls showed more obvious symptoms, or that the symptoms and signs were 
recognized differently by the girl, her family and healthcare professionals.  
Study II 
Study II explored a population of Swedish children and adolescents diagnosed with T1D 
under the age of 17, who were born in 1992-1993 and 1997-1998, and this showed that 
1,662/3,022 (55%) were boys. These results were consistent with previous studies that 
showed that males were slightly overrepresented in Swedish individuals with T1D (74). This 
tendency towards a more equal distribution, or a slight male overrepresentation, has been 
shown in other countries, which is interesting as females are overrepresented in the majority 
of other autoimmune diseases (9).  
In general, no statistically significant differences by sex was found in the prevalence of CD in 
the T1D population. Overall, 173 males had received both diagnoses before the age of 17, 
compared to 164 females (CD prevalence 10.4% versus 12% and p-value 0.15). This finding 
in Study II agreed with Study I. 
No differences according to sex were found in the epidemic cohort (52.9% male) compared 
to the post-epidemic cohort (49.1% male) (p-value 0.461). To our knowledge, no other 
studies are available that can provide comparable data about diagnoses of both CD and T1D 
during the epidemic, as we did not look at sex differences in the separately birth cohorts in 
Study I. Interestingly, the results from Study II did not agree with the cohort study regarding 
the general population in the Swedish CD epidemic (10), where the female to male ratio was 
more pronounced in the post-epidemic birth cohort, where 57 of the 89 children diagnosed 
with CD were girls (64%). 
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The results of Study II may indicate that the T1D population, regardless of the Swedish CD 
epidemic, were more at equally risk of developing CD, irrespective of the gender.   
Study III 
In Study III, the T1D population from the BBD study had an overrepresentation of boys 
(1,515/2,705, 56%), in agreement with previous mentioned review (9) and Study II.  
The endpoint of Study III was the CD autoimmunity response at T1D diagnosis. The 
presence of the CD biomarker tTG at the time of T1D diagnosis, showed statistically 
significant differences in sex, with 84 girls (5.48%) showing CD autoimmunity, compared 
to 64 boys (4.31%) (p-value 0.0013). Sex differences were also seen when we analysed 
borderlines and positive values separately.  
These findings indicated that CD autoimmunity was more frequent in girls at T1D onset. This 
sex difference needs to be explored further to evaluate if it maintains when CD diagnosis is 
set as the endpoint. 
Study IV 
Study IV showed male overrepresentation in the T1D cohort, as in previously mentioned 
review (9) and Studies II and III in this thesis.  
With regard to CD autoimmunity in Study IV, we found that 77 females and 74 males had 
positive tTG, while the prevalence of CD autoimmunity was slightly higher at 8.4% for 
females and 6.6% for males, but it was not statistically significant (p-value 0.12). 
The overall female to male ratio was similar regarding the children with both CD and T1D. 
The female to male ratio of children diagnosed with CD before T1D diagnosis was not 
statistically significantly different, as 17 out of the 32 children were females. Furthermore, 
among the 2,003 children with T1D screened for CD, 55 females and 58 males were 
diagnosed with CD. In addition, only one of the children with positive anti-tTG and normal 
biopsies was a girl. Thus, of the 145 children and adolescents with CD and T1D, 72 were 
girls and 73 were boys (p-value 0.2) (Table 7).  
Table 7. Prevalence according to sex. P-values > 0.05 were consider non-significant. 
 
This means that the results in study IV were consistent with the results in Studies I and II 
when it came to sex ratio.  
Study IV had CD diagnosis as the endpoint and there was considerable overlapping between 
this study and study III with regard to the subject who took part in them. The differences in 
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the results can be attributed to different methodologies. Study III only considered CD 
autoimmunity at T1D diagnosis and included some children with known CD before the T1D 
diagnosis. In contrast, Study IV adopted a CD case-finding approach after the T1D diagnosis. 
In summary, in contrast to other autoimmune diseases, boys with T1D were in majority 
compare to girls, and seemed to have the same risk to develop CD as girls with T1D. This 
risk was not influenced in either sex for individuals born during or after the Swedish CD 
epidemic. 
 
6.6 REFLECTIONS ON AGE DATA 
Study I 
The mean age at diabetes diagnosis was 6.8 years (range 0.17 to 16.7 years) among the 
children with both CD and T1D. This included the children with CD diagnosed before T1D 
and the children diagnosed by screening or due to symptoms. The mean age at CD diagnosis 
was 8.3 years (range 0.5 to 19.4 years).  
Study II 
Overall, the children and adolescents with T1D in the post-epidemic cohort were diagnosed 
with CD at a statistically significant younger age (mean 9.4 years) compared with children 
and adolescents born during the epidemic (11.0 years) (p-value 0.002). 
The age at CD diagnosis in T1D according to sex showed some statistically significant 
differences. In the post-epidemic cohort, the boys were 2.1 years younger at CD diagnosis, 
with a mean of 9.8 years compared to 11.9 years in the epidemic cohort (p-value 0,003). 
Also, the girls in the post-epidemic cohort were 1.1 year younger (9.1 years) compared to 
girls born during the epidemic (10.2 years). However, this was not statistically significant 
different (p-value 0.127).  
While there was no statistically significant difference at age at diagnosis of T1D for the 
children with CD between the cohorts (8.3 years compared to 8.5 years, p-value 0.707), the 
mean age at T1D diagnosis was significantly lower in the group diagnosed with both T1D 
and CD than in children diagnosed with T1D only (8.4 years compared to 9.8 years, p-value 
<0.001). 
Study III 
We studied the presence of the CD biomarker tTG in this T1D population. The median age of 
the children at T1D diagnosis was 10.1 years, with a slightly sex difference variation: 9.9 
years in girls and 10.9 in boys.  
More than half of the T1D children were in the age range between 5-14. The presence of tTG 
in these different groups showed no significant difference (Figure 23). 
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Figure 23. Description of the proportions of age groups in the T1D population, and the 
percentage of the children and adolescents with tTG positive or borderline.  
 
We appreciated a tendency to a lower percentage in the youngest group. Subsequently, we 
controlled the subgroup of children younger than two years of age (n=76, 2.8% of the study 
population), and found that none of these young children had positive tTG, and only two had 
borderline tTG.  
Study IV 
With regard to the prevalence of CD by age range in children withT1D in Study IV, we 
calculated age, distribution and proportion of screened children. There was no normal 
distribution and the number of very young children was small (Figure 24 and Figure 25).  
 
Figure 24. Distribution of age at diagnosis of CD, by screening, in 113 children and 






Percentage of children and adolecents with T1D, 
according to age (%) and presence of tTG (%)





    
 
Figure 25. Proportion of age at diagnosis of CD, diagnosed by screening, in the 113 
children and adolescents with T1D. 
 
When we compared Figure 24 with Figure 25, we noted that the proportion with a CD 
diagnosis by screening seemed to be following the total amount of children with T1D in each 
category.  
As expected, we found a difference in mean age between the children diagnosed with CD 
before T1D and the children diagnosed with CD after the T1D diagnosis (Table 8). 
 
 
Table 8. Age at diagnosis of T1D and CD, and interquartile range (IQR), with the low 1st 
quartile and the high 3rd quartile in brackets. 
 
 
Age differences were evaluated in various aspects. One finding was that the individuals with 
T1D and CD were statistically significant younger at the T1D diagnosis than the individuals 
with T1D that did not developed CD in childhood. This observation was in accordance with 
some previous studies (118, 167, 178, 179), but not all (175, 180). This highlighted the need 
for more research in this aspect.  
Furthermore, the children in the post-epidemic cohort were diagnosed with CD at a younger 
age. One possible explanation is that the 1997-1998 cohort may have been screened more 
often for CD at T1D diagnosis and for the first years after that than the epidemic cohort. The 
possible causes for this could be that screening in children with T1D was less common in the 
beginning of the 1990’s, the referral sometimes was postponed, and the general awareness for 
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6.7 PROPOSAL FOR FUTURE SCREENING 
 
The findings in this thesis supports that the screening procedure for diagnosing CD in 
children and adolescents with T1D can be improved.  
From Study I we can suggest that all children with T1D should be screened, at the time of 
T1D diagnosis, and at least the first two years after that. In Studies III and IV we found that 
children without high-risk HLA may not need further screening. In addition, in Study IV, 
we showed that tTG levels that were 10 times above the ULN were a reliable way to 
diagnose CD and avoid invasive biopsies. 
Figure 26 is a simplified proposal for a future screening procedure.  
 
Figure 26. A simple proposed algorithm for diagnosing CD by screening children and 
adolescents with T1D.  
1. Children and adolescents diagnosed with CD before their T1D diagnosis do not need to 
be screened. The others should be screened.  
2. The CD screening includes CD biomarker tTG antibodies, total IgA and HLA 
genotyping.  
3. If the children do not have HLA DQ2 or HLA DQ8 then further screening for CD is not 
necessary. 
4. If the CD biomarker is negative, the screening should be repeated later, preferably 
during the first two years after their T1D diagnosis. If IgA deficiency is diagnosed, then 
other biomarkers of IgG type should be used for screening for CD. 
5. If children have an IgA deficiency, and other CD biomarkers were positive, they should 
be referred for an endoscopy to retrieve biopsies. 
6. Children with positive tTG autoantibodies should be divided into two groups depending 
of the level of the CD biomarker, namely under and over 10 times the limit of normal. 
7. Children with tTG under 10 times the limit of normal should have an endoscopy to 
retrieve biopsies. 
8. If the biopsy results are normal, the screening should be repeated later. How often, and 
after how long, has not been decided. 
9. If the biopsy results show mucosal damage consistent with CD, the diagnosis should be 
given. 
10. Children with tTG over 10 times above the limit of normal, in two separate samples, 













7 CONCLUDING REMARKS 
 
A high prevalence of CD in Swedish children and adolescents with T1D was found, both in 
Stockholm and at a national level. Every tenth child and adolescent with T1D in Sweden also 
had CD. The majority of children diagnosed with CD had positive CD biomarkers at the 
diagnosis of T1D or seroconverted during the first few years after that. We therefore 
recommend that patients are screen for CD when they are diagnosed with T1D, and, if that 
screening is normal, they should be tested at least yearly the first two years after that. 
The prevalence of CD during and after the Swedish CD epidemic was found to be similar in 
children and adolescents with T1D. Thus, the T1D population at high-risk for developing CD 
may not be affected by environmental factors as the general population. This knowledge may 
be considered when planning both long-time observational studies regarding trigger factors 
for CD and interventional studies that aim to prevent CD. 
HLA typing, which was included in the screening procedure for diagnosing CD, played a 
limited role in children and adolescents with T1D. Thus, HLA typing could be reserved for 
identifying the patients that would not be at-risk for developing CD and could avoid 
recurrently screening for CD. This would be approximately 8% of the T1D population. 
High levels of the CD biomarkers tTG in the peripheral blood was prognostic for CD in 
children and adolescents with T1D. When the CD biomarker tTG was 10 times above the 
ULN it reliably prognosed CD. Approximately, half of the children and adolescents with T1D 
could thus avoid pre-anaesthesia fasting and invasive biopsies, and healthcare costs could be 
reduced. We suggest that children and adolescents with T1D should be included in national 




8 FUTURE PERSPECTIVES 
 
The overall aim of the studies included in this thesis was to provide more knowledge about 
CD in children and adolescents with T1D, but there is still so much more that I want to know. 
I want to continue my research in order to understand more about what triggers CD and T1D 
and their co-existence.  
CD screening has already been improved in clinical practice, due to the introduction of new 
guidelines. However, some important aspect of the optimal timing for CD biomarker tests 
remain unresolved. One main challenge is to validate how often, and for how long after their 
T1D diagnosis, children and adolescents should be screened for CD. 
It may be possible to stratify, and adapt, screening schedules for CD in a more individualized 
way. As CD is more common in children diagnosed with T1D earlier in life, younger children 
may need to be screened more often, and for a longer period of time, than adolescents who 
are diagnosed with T1D. I am also interested in validating if the different risks posed by 
HLA genes, together with age of onset of T1D, could contribute to a more individualized 
screening algorithm.  
Furthermore, several aspects of the accuracy of tTG as a predictor for CD need to be 
investigated. For example, it would be interesting to validate the no biopsy approach in 
children and adolescents with T1D, which is proposed in this thesis, in other non-Swedish 
T1D populations. Another aspect of our results that needs to be followed up is whether tTG 
that is seven times above the ULN would predict CD in other T1D and non-T1D populations. 
I would also like to explore how low tTG levels change over time after a T1D diagnosis and 
their predictive value for diagnosing CD in T1D populations. Multicentre and multinational 
collaborations, using only one type of serology test for tTG, would provide a good research 
approach.  
Nevertheless, diagnosis with serology (CD biomarkers) and histology (biopsies) is not 
perfect. The diagnostic pathway depends on whether the patients are on a diet that contains 
gluten and, even then, the histopathological changes can be mild, or patchy, which poses 
specific diagnostic challenges. That is why new diagnostic tools and methods are more than 
welcome. For example, the immunological effects of pathogenic gluten peptides in peripheral 
blood after oral gluten challenges needs to be measured in children and adolescents with 
T1D. Another method that needs to be validated in the T1D population is using video capsule 
endoscopy to complement serological biomarkers when diagnosing CD. With regard to the 
future, nanotechnology could offer new solutions for both diagnostic accuracy and maybe 
even for immunomodulation and disease control. 
The Swedish CD epidemic did not affect the prevalence of CD in children at-risk for diabetes 
in the otherwise healthy population. It would be interesting to find out if there were any 
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differences in the incidence of T1D during and after the Swedish CD epidemic. We hope that 
the result of our ongoing register study will be able to answer this question.  
In parallel, studies to assess whether the prevalence of CD in other at-risk populations was 
affected by the Swedish CD epidemic in childhood will provide more information about the 
pathogenesis of CD. For example, a study using several Swedish registries could compare 
first-degree family members to individuals with CD.  
There are a number of other important, unresolved research challenges. A key question that 
needs to be answered is how to prevent the development of CD, especially in high-risk 
groups. Several ongoing longitudinal prospective birth-cohorts’ studies may prove helpful in 
establishing this in the near future.  
Last, but not least, I would like to explore how to make daily life easier for children and 
adolescents with co-existing CD and T1D. Studies about how children and adolescents 
comply with their gluten-free diet, and the specific challenges they face, may improve their 
clinical management. In addition, new technology and telemedicine could provide additional 
support. We also need to evaluate overall, and disease-specific, quality of life tools for 
children and adolescents with both CD and T1D. This would enable us to compare them with 
children and adolescents with just CD or T1D. Exploring these important fields would enable 




9 POPULAR SCIENCE RESUME 
 
Coeliac disease in children and adolescents with type 1 diabetes  




Many children with type 1 diabetes have coeliac disease 
Coeliac disease (CD) is more common in children and adolescents with type 1 diabetes (T1D). We explored the 
prevalence of CD in children and adolescents with T1D and found that one in ten children with T1D was also 




CD is a medical condition that leads to intestinal damage. It is the mucosa of the small intestine that becomes 
inflamed and that inflammation is due to the body´s reaction towards gluten. The body misunderstands the 
signals and causes damage to the intestinal mucosa, which is completely or partially destroyed. “Autoimmune 
disease” refers to the kind of illness where our immune system attacks and destroys healthy cells in our body. 
CD is therefore an autoimmune disease. 
 
CD is a common condition in the general population. About one in 100 people in the Western world suffers 
from this disease. CD is more common among women and two out of three patients are female. This is also 
one of the most common chronic diseases among children and adolescents in Sweden. 
The number of people diagnosed with CD depends on several different factors. The number of children with 
CD is different in different regions, both within Sweden and among neighbouring countries. The prevalence 
also varies within the same population. In Sweden, there was a dramatic increase in CD in young Swedish 
children between 1984 and 1996, when the number of cases of CD quadrupled. This period was named “The 
Swedish epidemic of coeliac disease”. 
 
For the development of CD, gluten intake is required, as well as a combination of genetic predisposition and 
environmental factors. Today, knowledge is still insufficient as to why some people with proven heredity 
develop the disease, whereas others do not. 
 
The investigation of suspected CD can be started with a blood test. Nowadays, the mostly used antibodies are 
called anti-tissue transglutaminase (tTG). The test results determine how to proceed in order to get the 
diagnosis. The diagnostic protocol includes a medical examination with a flexible tube (gastroscope) that goes 
through the mouth into the small bowel. Through the gastroscope, small tissue samples (biopsies) are taken 
from the small bowel. The biopsies are then analysed under a microscope to assess intestinal damage. If tTG 
levels are found to be very high in two separate samples, the blood tests results are considered sufficient to 
diagnose CD.  
 
The possibility of avoiding biopsies is a real advantage. On the one hand, it is beneficial for the child, who 
does not need to fast and be subjected to anaesthesia and a gastroscopy examination. It provides advantages 
for the family, because the diagnosis that is just based on blood samples is less time-consuming. In addition, it 
saves the healthcare system time and uses more cost-effective methods to provide a diagnosis, without the 
need to perform invasive procedures to take biopsy samples. 
 
 
Type 1 diabetes 
T1D is a chronic disease that makes  the body unable to metabolize  sugar, which is our most important 
source of energy. The hormone insulin works like a key that opens the door for sugar to enter the cell as fuel 
 
T1D is an autoimmune disease. The ß-cells in the pancreas, where the insulin is produced, are damaged. 
When many of these cells  stop working, the sugar stays in the blood without entering the cells, causing the 
blood sugar to become high. When the blood sugar level becomes steadily higher than normal, the condition 
is called diabetes. 
 
The prevalence of T1D in Sweden is the second highest in the world. Only Finland has a higher figure. 
Around 50,000 individuals have T1D in Sweden and about 7,000 are children and young people. Every year, 




For T1D to develop, a combination of genetic predisposition and environmental factors are required. Today, 
knowledge is still insufficient as to why some people with proven heredity develop the disease, whereas 
others do not. 
 
T1D is diagnosed with blood tests—samples are also taken regarding diabetes autoantibodies, which can help 
to distinguish between different types of diabetes. 
 
 
Coeliac disease in children and adolescents with type 1 diabetes 
CD is more common in children and adolescents with T1D worldwide—the prevalence varies between 1.6% 
and 16%. In Sweden, other local studies showed that about 10% of children with T1D had CD. 
 
The link between CD and T1D is explained by the fact that the diseases have a common heredity, as they 
share the same genes. The vast majority of children with T1D (approximately 90%) have risk genes for CD. 
The risk genes are human leukocyte antigen (HLA) DQ2 and DQ8. They are located on chromosome 6. 
 
Due to the shared genetic risk between CD and T1D, children with T1D are screened for CD. A blood test to 
measure tTG levels is used for the screening and if the tTG levels are increased a biopsy procedure is the 
recommended next step. The reason for this recommendation is the lack of reliable studies showing it is also 
safe to diagnose CD in children with diabetes with repeated results of high tTG antibodies. To diagnose CD with 
just blood samples, as in children without T1D, would avoid pre-anaesthesia fasting for the children with T1D, 
and healthcare costs could be reduced.  
  
 
Overall purpose of this dissertation and main objectives 
The overall purpose of this dissertation was to expand current knowledge about CD in children and 
adolescents with T1D. 
The specific objectives were as follows: 
• To investigate the prevalence of CD in children and adolescents with T1D in Stockholm (Study I) 
and in Sweden (Study II). 
• To compare the prevalence of CD in children with T1D born before (Study I), during and after 
(Studies I and II) the Swedish CD epidemic,  
• To find out if CD screening in children and adolescents with T1D could be improved (Studies I, III 
and IV), 
• To elucidate  risk genes for CD in children and adolescents recently diagnosed with T1D, in relation 
to the coeliac biomarker tTG and diabetes- specific autoantibodies  (Study III). 
• To investigate if the no biopsy approach can be safe to diagnose CD in children and adolescents with 




In the first study, we examined the records for 1,151 paediatric patients at a diabetes clinic in Stockholm. We 
determined the number of children with T1D who also had CD in that city. We divided the patients into three 
subgroups: children born before, during and after the Swedish CD epidemic, and  performed a  retrospective 
review of their medical records. 
 
In the second study, we wanted to expand the data and investigate this relation at a national level and confirm 
the results from the first study. Therefore, we investigated the diagnoses T1D and CD in several Swedish 
databases. All people in Sweden who receive care in a hospital  receive one or more diagnoses. These 
diagnoses are collected as codes in national databases. In addition, all individuals with diabetes are offered to 
participate in a database concerning diabetes in particular. We created two groups: individuals born during the 
Swedish CD epidemic (1992–1993) and those born after the epidemic (1997–1998). The objective was to 
study those who developed T1D as a child and who also got the diagnosis of CD. 
 
In the third study, we used parts of a Swedish prospective cohort study of children and adolescents with 
diabetes. The study is called Better Diabetes Diagnosis (BDD) and covers virtually all children and 
adolescents under the age of 18 who have been diagnosed with diabetes in Sweden since 2005. We examined 
blood samples from 2,705 children and adolescents with T1D when they were diagnosed with T1D. The blood 
samples were analysed to find links between the risk genes HLA DQ2 and DQ8, the coeliac biomarker tTG 




In the fourth study, we also used BDD as a study base. We analysed information regarding 2,035 children and 
adolescents with T1D from the medical records kept by their diabetes clinics. In this way, we were able to 
describe the diagnostic procedures for the children who were also diagnosed with CD. 
 
All studies were approved by ethical review committees in Sweden. 
 
 
Results and implications 
We confirmed a high prevalence of CD in Swedish children and adolescents with T1D, both in Stockholm and 
at the national level. Every tenth child and adolescent with T1D in Sweden also has CD. Many of the children 
who were diagnosed with CD had positive coeliac biomarkers already at the time they were diagnosed with 
T1D. In addition, the vast majority were diagnosed with CD during the first two years with T1D. We 
therefore recommend screening children with T1D for CD at diagnosis and at least for the first two years.. 
 
The prevalence of CD in children and adolescents with T1D was similar in children born during and after the 
Swedish CD epidemic. Thus, the population with T1D, who has a high-risk of developing CD, may not be 
affected by environmental factors, such as different amounts of gluten as the general population was . This 
knowledge can be considered when planning both long-term observational studies and interventional studies 
on the prevention of CD. 
 
Genetic HLA tests for the risk genes DQ2 and DQ8 played a limited role in the diagnosis of CD in children 
and adolescents with T1D. Therefore, the determination of the HLA genes can be used to identify the 
approximately 8% of the T1D population who has no risk to develop CD. Consequently, these individuals do 
not need to undergo recurrent screenings. 
 
High levels of the CD biomarker tTG predicted CD in children and adolescents with T1D. When the tTG was 
10 times above the ULN it would have been safe and reliable to diagnose CD, without the need to confirm it 
with a biopsy. The children who met this requirement could thus avoid pre-anaesthesia fasting, and the 
gastroscopy procedure to take biopsies. Furthermore, a diagnosis without gastroscopy and biopsies is 
timesaving and reduces healthcare costs. Our suggestion is that national and international guidelines for the 





10  POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Celiaki hos barn och ungdomar med diabetes typ 1  




Många barn med diabetes typ 1 har celiaki 
Många barn som har diabetes typ 1 också har sjukdomen celiaki, som också kallas glutenintolerans. Vi har 
undersökt förekomsten av celiaki hos barn och ungdomar med diabetes typ 1 och påvisat att ett av tio barn i 




Celiaki är en sjukdom med skador på tarmen. Det är slemhinnan i tunntarmen som blir inflammerad, och 
inflammationen beror på att kroppen reagerar mot gluten. Kroppen missförstår signalerna och det blir skador i 
tarmluddet, som helt eller delvis förstörs. Mekanismen som leder till sjukdomar där de egna cellerna förstör 
egna celler eller organ kallas för autoimmuna sjukdomar. Celiaki är en autoimmun sjukdom.  
 
Celiaki är vanligt förekommande, cirka en person av hundra i västvärlden har glutenintolerans. Celiaki har 
ökat under de senaste trettio åren. Celiaki är vanligare i den kvinnliga delen av befolkningen –två av tre 
patienter är flickor eller kvinnor. Sjukdomen är dessutom en av de vanligaste kroniska sjukdomarna hos barn 
och ungdomar i Sverige. Hur många personer som får diagnosen celiaki beror på flera olika faktorer. Antalet 
barn med celiaki varierar i olika regioner, både inom Sverige, och mellan närliggande länder. Förekomsten av 
celiaki varierar också inom samma population. I Sverige förekom en dramatisk ökning av celiaki hos unga 
svenska barn mellan 1984 och 1996. Då fyrdubblades antalet fall. Denna tidsperiod kom att kallas ”Den 
svenska celiakiepidemin”.  
 
För att celiaki skall utvecklas krävs intag av gluten, samt en kombination av arvsanlag och miljöfaktorer. Idag 
är kunskapen fortfarande otillräcklig angående varför vissa personer med påvisad ärftlighet får sjukdomen och 
andra inte.  
 
Vid utredning av celiaki tar man blodprov. Nuförtiden används de antikroppar som kallas 
vävnadstransglutaminas (förkortas tTG). Vad som visas i provsvaret avgör hur man går vidare i diagnostiken. 
I det diagnostiska protokollet ingår en medicinsk undersökning där man via munnen för ned ett böjligt rör 
(gastroskop). Genom gastroskopet tas små vävnadsprover (biopsier) från tunntarmen och biopsierna 
analyseras sedan under mikroskop för att bedöma eventuell tarmskadan. Men om tTG visat sig vara mycket 
högt i två separata prov räcker dock blodprovsvaren för att kunna ge diagnosen.  
 
Det är en fördel i diagnostiken att kunna avstå biopsier. Dels är det en vinst för barnet som inte behöver fasta 
och utsättas för narkos och en gastroskopiundersökning, och dels är det en vinst för familjen eftersom den 
medicinska undersökningen med enbart blodprover är mindre tidskrävande. Därutöver är det en vinst också 




Sjukdomen diabetes typ 1 
Diabetes typ 1 är en autoimmun sjukdom som leder till att kroppen inte längre kan ta vara på socker, som är 
en viktig energikälla. Hormonet insulin är nyckeln som öppnar dörren för att sockret ska komma in i cellen så 
att kroppen får en normal ämnesomsättning. Om cellerna i bukspottskörteln, där insulinet tillverkas, skadas 
och slutar att fungera, stannar sockret kvar i blodet. Då blir blodsockernivån högre än normalt och det 
tillståndet kallas diabetes.  
 
Förekomsten av diabetes typ 1 i Sverige är den nästa högsta i världen. Bara Finland har högre siffror. Runt  
50000 individer har typ 1 diabetes i Sverige, och av dessa är ca 7000 barn och ungdomar. Per år insjuknar ca 
800 barn i Sverige. Antalet barn och ungdomar med diabetes typ 1 har ökat över tiden. I början av 2000-talet 




För att diabetes typ 1 skall utvecklas krävs en kombination av arvsanlag och miljöfaktorer. Idag är kunskapen 
fortfarande otillräcklig angående varför vissa personer med påvisad ärftlighet får sjukdomen.  
 
Diabetes typ 1 diagnostiseras med ett blodprov. I samband med diabetesdiagnosen tas även prover angående 
diabetesautoantikroppar som kan hjälpa till att skilja mellan olika typer av diabetes. 
 
 
Celiaki hos barn och ungdomar med diabetes typ 1 
Sjukdomen celiaki är vanligare hos barn och ungdomar med diabetes typ 1. Antalet barn som har båda 
sjukdomarna varierar globalt mellan 1,6 % och 16 %. I Sverige har cirka 10 % av barn med diabetes typ 1 
också celiaki. 
 
Sambandet mellan celiaki och diabetes typ 1 förklaras med att sjukdomarna har gemensam ärftlighet, att de 
delar samma gener. De allra flesta barn med diabetes typ 1 (cirka 90 %), har riskgener för celiaki. 
Riskgenerna är: humant leukocytantigen (HLA) DQ2 och DQ8. De finns på ett område i arvsanlaget, på 
kromosom 6.  
 
På grund av det genetiska sambandet mellan sjukdomarna undersöker vi idag barn med diabetes typ 1 för att 
se om de också har celiaki. Det kallas att screena. Även här tar man blodprov för att mäta antikropparna tTG, 
men även om tTG är mycket högt i två prover i rad är det dock inte rekommenderat att redan där ge diagnosen 
celiaki. Man går istället vidare med biopsier. Anledningen till det är att man saknat undersökningar som visar 
att det är tillförlitligt att ge diagnosen celiaki när barn med diabetes typ 1 har höga tTG. Med en undersökning 
utan biopsier skulle vissa barn kunna undvika att fasta före anestesin och själva endoskopiundersökningen, 
och det skulle vara mer kostnadseffektivt.  
 
 
Övergripande syfte med denna avhandling och huvudmålen 
Det övergripande syftet med denna avhandling var att utöka aktuell kunskap om celiaki hos barn och 
ungdomar med diabetes typ 1. 
 
De specifika målen var följande: 
• Att undersöka förekomsten av celiaki hos barn och ungdomar med diabetes typ 1 i Stockholm  
(studie I) och i Sverige (studie II). 
• Att jämföra förekomsten av celiaki hos barn med diabetes typ 1 födda under den svenska 
celiakiepidemin, dels med barn med diabetes typ 1 födda före nämnda epidemi (studie I), och även 
med barn födda efter (studier I och II). 
• Att ta reda på om celiaki-screeningen hos barn och ungdomar med diabetes typ 1 skulle kunna 
förbättras (studier I, III och IV), och i så fall hur. 
• Att undersöka riskgenerna HLA DQ2 och DQ8 hos barn och ungdomar som nyligen diagnostiserats 
med diabetes typ 1, samt att belysa dessa geners förekomst i relation till celiaki-biomarkören tTG 
och autoantikroppar vid diabetes (studie III). 
• Att utreda om det kan vara säkert att diagnostisera celiaki hos barn och ungdomar med diabetes typ 1 




I den första studien undersökte vi journalerna för 1151 barn på en diabetesklinik i Stockholm. Vi tog reda på 
hur många av barnen med diabetes typ 1 som hade celiaki. De av barnen som hade båda sjukdomarna delade 
vi in i tre undergrupper: barn födda före, under och efter den svenska celiakiepidemin, och utförde sedan en 
omfattande retrospektiv granskning av deras journaler. 
 
I den andra studien ville vi utöka underlaget och ta reda på hur det låg till på ett nationellt plan. Vi ville 
bekräfta resultaten från första studien avseende både det totala antalet barn och andelen av barn och ungdomar 
med celiaki bland barnen med diabetes typ 1, både under och efter den svenska epidemin. Därför gjorde vi en 
analys av existerande diagnoser i olika svenska databaser. (Alla personer i Sverige som får vård på sjukhus får 
en eller flera diagnoser. Dessa diagnoser samlas som koder i nationella databaser. Dessutom erbjuds alla 
individer med diabetes att delta i en databas angående just diabetes). Vi skapade två grupper: individer födda 
under den svenska celiakiepidemin, 1992–1993, och individer födda efter densamma, 1997–1998. Detta för 
att studera vilka som fått diabetes typ 1 som barn, och bland dem, vilka som också fick celiakidiagnosen. 
 
I den tredje studien använde vi delar av en svensk prospektiv studie av barn och ungdomar med diabetes. 
Studien heter Bättre Diabetes Diagnos (BDD), och omfattar i stort sett alla barn och ungdomar under 18 år 
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som fått diagnosen diabetes i Sverige sedan 2005. Vi undersökte blodprover från 2705 barn och ungdomar 
med diabetes typ 1, vilka tagits i samband med diabetesdiagnosen. Blodproverna analyserades avseende 
kopplingarna mellan riskgenerna HLA DQ2 och DQ8, celiaki-antikroppar tTG och autoantikroppar för 
diabetes (IAA, GADA, IA2A och ZnT8).  
 
Även i den fjärde studien använde vi BDD som studiebas. Vi kombinerade information angående 2035 barn 
och ungdomar med diabetes typ 1 med journaldata från barnens respektive diabetesklinik. På så vis kunde vi 
analysera vilka, hur och på vilket sätt barnen fått sin celiakidiagnos. Vi undersökte om det kan vara 
tillförlitligt att diagnostisera celiaki hos barn och ungdomar med diabetes typ 1 utifrån endast blodprover. 
 
Alla studier godkändes av etiska kommitteen i Sverige. 
 
 
Resultat och implikationer 
Vi bekräftade en hög förekomst av celiaki hos svenska barn och ungdomar med diabetes typ 1, både i 
Stockholm och på nationell nivå. Var tionde barn och ungdom med diabetes typ 1 i Sverige har även celiaki. 
Många av barnen som fick diagnosen celiaki hade positiva celiaki-biomarkörer redan i samband med att de 
fick sin diabetes typ 1-diagnos. Dessutom fick de allra flesta celiakidiagnosen under de första två åren med 
typ 1 diabetes. Därför rekommenderar vi att man screenar barn med typ 1 diabetes vid diabetesdiagnosen och 
åtminstone de första två åren efter diabetesdiagnosen.  
 
Förekomsten av celiaki hos barn och ungdomar med diabetes typ 1 var densamma under och efter den 
svenska celiakiepidemin. Detta tyder på att populationen med diabetes typ 1 med hög risk för att utveckla 
celiaki, kanske inte påverkas av olika glutenmängder som den allmänna befolkningen gör. Denna kunskap kan 
tas med i beräkningen när man planerar både långvariga observationsstudier och interventionella studier 
avseende förebyggandet av sjukdomen celiaki. 
 
HLA riskgenerna DQ2 och DQ8 hade en begränsad roll i samband med diagnosen av celiaki hos barn och 
ungdomar med diabetes typ 1. Därför kan bestämningen av HLA generna användas för att identifiera de cirka 
8 % av diabetes typ 1-populationen som inte är i riskzonen för att utveckla celiaki. Dessa individer behöver 
följaktligen inte genomgå återkommande celiaki-screeningar. 
 
Höga nivåer av celiaki-biomarkören tTG prognosticerade celiaki även hos barn och ungdomar med diabetes 
typ 1. När celiaki-biomarkörerna tTG var över tio gånger den normala gränsen var det tillförlitligt att 
diagnostisera celiaki, utan att bekräfta det med en biopsi. Barnen som uppfyllde detta krav med höga celiaki-
biomarkören tTG skulle därför kunna undvika gastroskopin för att ta biopsier. Celiakidiagnos utan biopsi är 
skonsamt för barnet och familjen. Vidare är en diagnos utan gastroskopi och biopsier tidsbesparande och 
minskar hälso- och sjukvårdskostnaderna. Vi rekommenderar att riktlinjer för celiakiutredningen hos 





11  RESUMEN CIENTÍFICO DIVULGATIVO 
 
Enfermedad celíaca en niños y adolescentes con diabetes tipo 1 
Cribado, diagnóstico y prevalencia 
 
 
Numerosos niños con diabetes tipo 1 padecen también la enfermedad celíaca  
La enfermedad celíaca (EC) es más habitual en niños y adolescentes con diabetes de tipo 1 (T1D). Hemos 
estudiado la prevalencia de la EC en niños y adolescentes con T1D y hemos observado que uno de cada diez 




La EC es un trastorno que provoca daños intestinales. La mucosa del intestino delgado se inflama debido a la 
reacción del organismo hacia el gluten. El organismo no interpreta correctamente las señales y provoca daños 
en la mucosa intestinal, la cual se destruye de forma total o parcial. Se entiende por «enfermedad 
autoinmune» un tipo de enfermedad en la que nuestro sistema inmunológico ataca y destruye las células sanas 
de nuestro cuerpo. La EC es, por lo tanto, una enfermedad autoinmune. 
 
La EC es un trastorno común en la población; en torno a una de cada cien personas en el mundo occidental la 
sufre. Es más habitual entre las mujeres: dos de cada tres pacientes lo padecen. Asimismo, se trata de una de 
las enfermedades crónicas más extendidas entre los niños y adolescentes de Suecia. 
 
El número de personas a las que se les diagnostica la enfermedad celíaca depende de diversos factores. Por 
ejemplo, la cifra de menores con celiaquía es diferente en las distintas regiones, tanto en Suecia como entre 
los países vecinos. La prevalencia también varía dentro de la misma población. Por ejemplo, en Suecia se 
produjo un enorme aumento de la EC en la población infantil entre 1984 y 1996, ya que se cuadruplicó el 
número de casos de celiaquía. Se denomina a este periodo «la epidemia sueca de enfermedad celíaca». 
 
Para que se desarrolle la EC se requiere la ingesta de gluten, así como una combinación de predisposición 
genética y factores ambientales. Hoy en día, todavía no se sabe a ciencia cierta por qué desarrollan la EC 
algunas personas cuya predisposición genética se ha constatado, mientras que otras no lo hacen. 
 
La investigación de la sospecha de la EC puede iniciarse con un análisis de sangre. Hoy en día, los 
anticuerpos más utilizados se denominan antitransglutaminasa tisular (tTG). Los resultados de la prueba 
determinan cómo proceder para obtener el diagnóstico. El protocolo de diagnóstico incluye una prueba 
médica que se realiza con un tubo flexible (gastroscopio), el cual permite observar el intestino delgado a 
través de la boca. A través del gastroscopio, se toman pequeñas muestras de tejido (biopsias) del intestino 
delgado. Dichas biopsias se analizan a continuación con un microscopio para evaluar el daño intestinal. Si se 
detectan niveles de tTG muy elevados en dos muestras distintas, los resultados de los análisis de sangre se 
consideran suficientes para diagnosticar la enfermedad celíaca.  
 
La posibilidad de evitar las biopsias constituye toda una ventaja. Por un lado, resulta beneficiosa para el niño, 
que no necesita ayunar y someterse no solo a la anestesia, sino también a una gastroscopia. Por otro lado, 
supone un alivio para la familia, ya que el diagnóstico verificado únicamente mediante muestras de sangre es 
más breve. Además, el sistema de salud puede ahorrar tiempo, al utilizar métodos más económicos que 




Diabetes de tipo 1 
La diabetes de tipo 1 es una enfermedad crónica que hace que el organismo ya no pueda metabolizar el 
azúcar, nuestra fuente de energía más importante. La hormona insulina funciona como una llave que abre la 
puerta para que el azúcar entre en las células a modo de combustible. 
 
La diabetes de tipo 1 es una enfermedad autoinmune. Las células ß del páncreas, en las que se produce la 
propia insulina del cuerpo, están dañadas. Cuando muchas de estas células que producen insulina dejan de 
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funcionar, el azúcar permanece en la sangre sin penetrar en las células, lo que provoca que el nivel de azúcar 
en sangre se incremente. Cuando esto ocurre, el trastorno se denomina diabetes. 
 
La prevalencia de la diabetes de tipo 1 en Suecia es la segunda más alta del mundo. Solo Finlandia tiene cifras 
más altas. Alrededor de 50 000 personas padecen T1D 1 en Suecia, de las que en torno a 7000 son niños y 
jóvenes. Cada año, unos 800 menores desarrollan la enfermedad en Suecia.  
 
Para que se desarrolle la diabetes de tipo 1, se requiere una combinación de predisposición genética y factores 
ambientales. Hoy en día, todavía no se sabe a ciencia cierta por qué algunas personas con factores hereditarios 
comprobados desarrollan la diabetes de tipo 1, mientras que otras no lo hacen. 
 
La diabetes de tipo 1 se diagnostica mediante análisis de sangre; también se toman muestras de los 
autoanticuerpos de la diabetes, que pueden ayudar a distinguir entre los diferentes tipos de diabetes. 
 
 
Enfermedad celíaca en niños y adolescentes con diabetes de tipo 1 
La celiaquía es más habitual en niños y adolescentes con diabetes de tipo 1 en todo el mundo: la prevalencia 
oscila entre el 1,6 % y el 16 %; en Suecia, ciertos estudios locales contemplan que en torno al 10 % de los 
menores con diabetes de tipo 1 padecen también la enfermedad celíaca. 
 
El vínculo entre la EC y la T1D se explica por el hecho de que las enfermedades tienen un componente 
hereditario común, ya que comparten los mismos genes. La inmensa mayoría de los menores con diabetes de 
tipo 1 (aproximadamente el 90 %) poseen genes que les predisponen a desarrollar la enfermedad celíaca. Los 
genes de riesgo son el antígeno leucocitario humano (HLA) DQ2 y DQ8, que se encuentran en un área del 
genoma, en el cromosoma 6. 
 
Debido al riesgo genético compartido entre la enfermedad celíaca y la diabetes de tipo 1, se realiza un cribado 
a los niños con diabetes de tipo 1 para conocer si son celíacos. La prueba se basa en un análisis de sangre que 
mide los niveles de tTG. Sin embargo, si los niveles de tTG son muy altos en dos pruebas distintas, no se 
recomienda que los niños y adolescentes con T1D obtengan el diagnóstico de enfermedad celíaca solo en 
función de dichas pruebas, a contrario de la recomendación para otros niños. La biopsia es el siguiente paso 
recomendado, y el motivo de esta recomendación es la falta de estudios fiables hasta este momento que 
demuestren que también es seguro diagnosticar la enfermedad celíaca en menores con T1D con niveles altos 
de anticuerpos tTG. Si se pudieses demostrar que se puede basar el diagnóstico únicamente en muestras de 
sangre, sin un examen médico que incluyera gastroscopia y biopsias, se podría evitar el ayuno previo a la 
anestesia a los niños con diabetes de tipo 1, al tiempo que se podrían reducir los costes sanitarios.  
 
 
Propósito general de la presente disertación y objetivos principales 
El propósito general de la presente disertación fue el de ampliar los conocimientos actuales sobre en niños y 
adolescentes con diabetes de tipo 1. 
 
Los objetivos específicos fueron los siguientes: 
• Investigar la prevalencia de la enfermedad celíaca en niños y adolescentes con diabetes de tipo 1 en 
Estocolmo (estudio I) y en Suecia (estudio II). 
• Comparar la prevalencia de la enfermedad celíaca en niños con diabetes de tipo 1 nacidos durante la 
epidemia sueca de enfermedad celíaca, en parte con menores con diabetes de tipo 1 nacidos antes de 
la mencionada epidemia (estudio I), y también con niños nacidos después (estudios I y II). 
• Conocer si se podría mejorar el cribado para la detección de celiaquía en niños y adolescentes con 
diabetes de tipo 1 (estudios I, III y IV) y, en caso afirmativo, investigar de qué manera. 
• Investigar sobre los genes que predisponen a la enfermedad celíaca en niños y adolescentes a los que 
se ha diagnosticado recientemente diabetes de tipo 1, y dilucidar la presencia de estos genes en 
relación con el biomarcador celíaco tTG y la presencia de autoanticuerpos en la diabetes (estudio 
III). 
• Investigar si el enfoque sin biopsia podría ser seguro para diagnosticar la enfermedad celíaca en 
niños y adolescentes con diabetes de tipo 1 (estudio IV). 
 
 
Estrategia de investigación 
En el primer estudio, examinamos los historiales de 1151 pacientes pediátricos en una clínica de Estocolmo 
especializada en diabetes. Llegamos a la conclusión de que numerosos niños con diabetes de tipo 1 padecen 
también la enfermedad celíaca en dicha ciudad. Asimismo, dividimos a los pacientes con ambas enfermedades 
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en tres subgrupos, compuestos por niños nacidos antes, durante y después de la epidemia sueca de celiaquía, 
respectivamente. A continuación, realizamos una revisión retrospectiva exhaustiva de sus historiales médicos. 
 
En el segundo estudio, quisimos ampliar los datos e investigar esta relación a nivel nacional. Nuestro objetivo 
era confirmar los resultados del primer estudio sobre el número total de niños, así como sobre la proporción 
de niños y adolescentes con enfermedad celíaca entre los menores con diabetes de tipo 1, durante y después 
de la epidemia sueca. Así, realizamos un análisis de los diagnósticos de EC y T1D existentes en varias bases 
de datos suecas. (Todas las personas que reciben atención en un hospital de Suecia reciben uno o más 
diagnósticos; tales diagnósticos se recogen en forma de códigos en las bases de datos nacionales. Además, se 
ofrece a todos los individuos con diabetes la posibilidad de aparecer en una base de datos relativa a la diabetes 
en particular). Creamos dos grupos: los individuos nacidos durante la epidemia sueca de celiaquía (1992-
1993) y los nacidos después de la epidemia (1997-1998). El objetivo era estudiar quiénes desarrollaron 
diabetes de tipo 1 durante la infancia y, de ellos, quiénes recibieron también el diagnóstico de la enfermedad 
celíaca. 
 
En el tercer estudio, usamos partes de un estudio sueco prospectivo de cohortes que se llevó a cabo con niños 
y adolescentes diabéticos. El estudio se denomina Better Diabetes Diagnosis (BDD) y abarca prácticamente a 
todos los niños y adolescentes menores de 18 años diagnosticados de diabetes en Suecia desde 2005. 
Examinamos muestras de sangre de 2705 niños y adolescentes con diabetes de tipo 1 cuando recibieron el 
diagnóstico de esta enfermedad. Se analizaron las muestras de sangre para encontrar vínculos entre los genes 
de riesgo HLA DQ2 y DQ8, el biomarcador de celiaquía tTG y los autoanticuerpos específicos en la diabetes 
(IAA, GADA, IA2A y ZnT8). 
 
Para el cuarto estudio también se recurrió al estudio BDD: combinamos los datos relativos a 2035 niños y 
adolescentes con diabetes de tipo 1 con los datos de los historiales médicos de las clínicas especializadas en 
diabetes. De esta manera, pudimos analizar qué niños fueron diagnosticados de enfermedad celíaca, así como 
describir la vía y el modo para llegar a dicho diagnóstico. 
 
Todos los estudios recibieron la aprobación de comités de revisión ética de Suecia. 
 
 
Resultados e implicaciones 
Se confirmó una alta prevalencia de la enfermedad celíaca en niños y adolescentes suecos con diabetes de tipo 
1, tanto en Estocolmo como a nivel nacional. Uno de cada diez niños y adolescentes con diabetes de tipo 1 en 
Suecia también es celíaco. Muchos de los menores diagnosticados de enfermedad celíaca ya tenían 
biomarcadores de celiaquía positivos cuando se les diagnosticó la diabetes de tipo 1. Además, a la gran 
mayoría se les diagnosticó la enfermedad celíaca durante los dos primeros años con diabetes de tipo 1. Por lo 
tanto, recomendamos realizar el cribado de EC a los niños con diabetes de tipo 1 en el momento del 
diagnóstico y al menos durante los dos primeros años a partir de dicho diagnóstico. 
 
La prevalencia de la enfermedad celíaca en niños y adolescentes con diabetes de tipo 1 fue similar en los 
niños nacidos durante y después de la epidemia sueca de enfermedad celíaca. Por tanto, la población con T1D, 
cuyo riesgo de desarrollar la EC es muy elevado, puede no verse afectada por factores ambientales, como las 
diferentes cantidades de gluten, como sí le sucedió a la población en general. Estos conocimientos pueden 
tenerse en cuenta al planificar tanto los estudios de observación a largo plazo como los estudios de 
intervención sobre la prevención de la enfermedad celíaca. 
 
Las pruebas genéticas de HLA para los genes de riesgo DQ2 y DQ8 desempeñaron un papel limitado en el 
diagnóstico de la enfermedad celíaca en niños y adolescentes con diabetes de tipo 1. Por lo tanto, la 
determinación de los genes HLA se puede utilizar para identificar en torno al 8 % de la población diabética de 
tipo 1 sin predisposición a desarrollar la enfermedad celíaca. En consecuencia, estas personas no necesitan 
someterse a exámenes periódicos de cribado de enfermedad celíaca. 
 
Los altos niveles del biomarcador celíaco tTG predijeron la enfermedad celíaca en niños y adolescentes con 
diabetes de tipo 1. Los biomarcadores de celiaquía tTG con niveles diez veces superiores al límite máximo de 
lo considerado normal resultaron fiables y seguros para diagnosticar la enfermedad celíaca de modo que la 
confirmación mediante biopsia no hubiese sido necesaria. Los niños que cumpliesen este requisito podrían así 
evitar el ayuno previo a la anestesia y el procedimiento de gastroscopia para tomar biopsias. Además, un 
diagnóstico sin gastroscopia y biopsias ahorra tiempo y reduce los costes de asistencia médica. En suma, 
sugerimos que las directrices nacionales e internacionales para el diagnóstico de la enfermedad celíaca 










First and foremost, I would like to express my deepest gratitude to all the children and 
adolescents, some of them now young adults, and their families, for participating in the 
research studies included in this thesis. 
 
I would also like to show my sincere gratitude to all the people who have helped and 
encouraged me, in all aspects, during the time of my Ph.D. studies. 
 
I would like to dedicate my sweetest memories to Lena Grahnquist, my first main 
supervisor, who sadly passed away in 2014. I am extremely grateful for her invitation to 
start this research project, and for sharing her enthusiasm and her strive for knowledge.  
She gave me the support I needed during my first years in paediatrics at Astrid Lindgren’s 
Children Hospital. I am glad she taught me to become an observant physician, and 
furthermore, an emphatic paediatrician. We became a good working team during my time at 
her department, and I remember my rotation at the inpatient ward for both gastroenterology 
and endocrinology as one of the most valuable and educational periods during my 
residency. As a supervisor for my thesis, we shared the ambition to improve the care of 
children that were screened for CD. It was a privilege to work and study under her 
guidance. Therefore, it was with great sorrow I said goodbye to her at her Associate 
Professor celebration, knowing that her time was to end soon. Without Lena, this thesis 
would have never been started, and this project would not have been completed either. She 
has been present in my thoughts and my heart, as well as in the core of this thesis. Her 
memory has given me the strength to pursue my goals. I send Lena my warmest and most 
sincere gratitude for all eternity      . 
 
Annelie Carlsson, my main supervisor. Thank you for taking over the baton and the 
responsibility for this project, and for encouraging me to continue this Ph.D. journey.  
I am grateful that we were able to remount and to plan the second part of my thesis 
together, and that you showed confidence in my ideas about the research approach and 
protocols. Thank you for taking time to always answering my questions so patiently, with 
your wisdom and extensive knowledge. Last but not least, I am beyond grateful for your 
personal and financial support! You created the opportunity for me to write this thesis.  
I wish we can continue working together in other projects to come! 
  
Eva Örtqvist, my co-supervisor, I am grateful you contributed to my most valuable time at 
the inpatient ward, and taught me plenty about diabetes type 1 in children and adolescents. 
You have a great ability to explain even the most difficult things in a simple way, which 
has taught me a lot! Thank you for your great patience when reading my drafts over and 
over again, including this thesis. I appreciate so much you were always ready to help me! 
 
Hans Hildebrand, my co-supervisor, thank you for sharing your wisdom and extensive 
knowledge on coeliac disease. I was honoured to contribute to your hospital-based 
outpatient coeliac clinic, even if it was for a short time. I am also filled with gratitude for 
your patience and valuable constructive criticism regarding both the manuscripts and this 
thesis. You have been a great teacher and writing support! 
 
72 
I would like to send my appreciation to my mentor, Carl-Johan Sundberg. I remember 
your teaching lessons on physiology as the warmest and most energizing way to learn about 
the human body. You were a strong role model, and inspired me to become a physician, 
since you showed me that research could be an important component of a doctor’s work 
life. I will always be thankful for your wise and thoughtful advice. It has been a privilege 
having you as a guide during my early steps in medicine, and a kind resource during my 
Ph.D. 
 
I also want to show my sincere gratitude to all co-authors: thank you for all the feed-back, 
comments, encouraging words and good collaboration. During these projects several 
medical students became physicians and co-authors: thank you Sophie Lantz, Filippa 
Frederiksen, Elin Udén, Anna Gustafsson, and Elsa Palmqvist for good teamwork.  
I also wish to sincerely give my appreciation for the longstanding collaboration to the BDD 
steering group, who let me be a part of this amazing and valuable study. Especially,  
I would love to express my appreciation to Qefsere Brahimi, for her assistance regarding 
databases, and my deepest gratitude to Sten A. Ivarsson for opening the research 
opportunity. 
 
Special thanks to other collaborators: Per Näsman for his exceptional statistical assistance, 
Kerstin Elfvin for teaching me all about CD biomarkers at her laboratory, nutritionists 
Erika Lidgren and Julia Strömblad Lenhoff for working with me and Lena on essays 
about compliance and the gluten free diet. I’m indebted to Annette Whibley, for her 
English proofreading and the editing of this thesis, and to Rocío Serrano for her help in the 
Spanish editing. In addition, I am deeply grateful for the possibility to adapt my newly 
discovered artist Stefan Oels’ symbolic painting “Vórtice del Sol”, with the help from my 
friend Diana Mehedintu’s sharp designer eyes for the cover picture.  
 
I am grateful for Karolinska Institutet support functions and courses. I wish to give my 
appreciation to the teachers and participating colleagues at the Research School for 
clinicians in epidemiology. The Epi-school has been the best research school ever, and  
I send special thanks to Ylva Trolle Lagerros for her never-ending smile and positive 
attitude, and to Michael Fored for those intensive days with tips on how to get published. 
 
I wish to acknowledge the support I received from the all the staff at the Department  
of Women’s and Children’s Health, with special mention to Astrid Häggblad and 
Carolina Rådestad for their extra help in the beginning and at the end of this Ph.D. 
project, respectively. I send a special note of thanks to the Karolinska library’s academic 
writing support Kristina, Anna and Gabriella for their enormously valuable input during 
individual coaching and to Love for showing me new tricks with Endnote. I owe many 
thanks to course leaders Anna and Ken: you shared your wisdom and extensive knowledge 
about presenting research in an amazing way! Please receive my virtual hugs. 
 
My appreciation to all my head of departments, bosses and colleagues over these years: 
thank you for all your support and understanding, you help me balance my clinical work 
with research activities over a long time. Jag vill också tacka alla tidigare kollegor på Astrid 
Lindgrens sjukhus. Ett speciellt tack till Aida Walhgren och Erica Bonns för våra samtal, 
möten och samarbeten under ST-tiden. Encontré mi segunda casa laboral con el Grupo 
Pries, en Málaga, y quiero expresar mi especial agradecimiento a mi jefe Juan Pérez, quien 
supo reconocer mis méritos suecos, y a mi estimada Cinta Cabrera, nuestra coordinadora. 
Muchas gracias a todo el personal especializado en sus áreas por el trabajo que 
compartimos día a día en las clínicas; gracias por vuestro esmero y colaboración. También 
quiero expresar mis sincero agradecimientos a mis compañeros pediatras del Grupo Pries, 
 
 73 
por avalar nuestro empeño. Un fuerte agradecimiento a todos los compañeros de 
gastroenterología en Málaga, y a los integrantes de la Asociación Andaluza de 
Gastroenterología, Hepatología y Nutrición Pediátrica, con los que he compartido prolíferos 
almuerzos, encuentros, cursos y congresos. Incluyo en estos encuentros lúdicos y traslado 
mi gratitud a las doctoras Amparo y Luz que me han brindado su amistad. 
 
Friends, vänner, amigos! I am grateful for all support and assistance. For being here and 
there, for laughing times, for sharing experiences... Quiero trasladar mi más sincera gratitud 
a Macu, mi amiga del alma, por estar siempre ahí como una hermana. Gracias a Natalia 
por compartir nuestras vidas desde esa infancia en el club. Doy gracias a mis maestros y 
compañeros del Castelli y a los del Colegio Nacional de Buenos Aires, ya que mi vida sin 
Uds. no sería la misma. Agradezco a Paula, Vir, Noe y Fer, por nuestros primeros pasos en 
las aulas y los reencuentros tan bonitos. Y a mi querido grupo de las siete: Nati, Jime, Den, 
Ale, Andy y Tam, por las inquietudes que nos han movido durante todos estos años y por 
seguir compartiendo los momentos que se crean durante nuestros viajes. Un agradecimiento 
también a los chicos, por su amistad: Dani, Fefi, Franco, Fran, Carlos, Yuki, Taba y 
Mariano. Para las Mami Chulis va un fuerte abrazo de gratitud, por todos los desayunos 
juntas y las ganas de compartir nuestras experiencias de madres. Quiero también dar gracias 
de corazón a mi coro, Alicia y Sara, que constituyen el mejor apoyo imaginable, nuestro 
camino conjunto me moldea de una forma significativa para la búsqueda del Ser. Extiendo 
por eso mi agradecimiento a mis otros compañeros e instructores de la escuela Clairvision 
y, entre ellos, en especial a Elsa por su dedicación, tacto y sabiduría. Quisiera además 
agradecer a mis amigas Ana y Paola por vuestro apoyo incondicional y animadas charlas 
desde nuestros primeros encuentros en ALB. Otro agradecimiento para Eric y Camilla, por 
compartir vuestra música en nuestra amistad. Un abrazo de gratitud también a María y 
Gastón por vuestra sincera amistad, bondad y repetitiva hospitalidad. För utvecklande 
trevliga själsmöten vill jag tacka astro-gänget, Tina, Helén, Eva och Johan, samt Stefan 
och Helena. Tack till Liselott och Per för vår nya fina vänskap i Rincón. Sist i listan men 
varmaste i hjärtat, vill jag tacka dig Anna för de finaste möten genom åren, för att du alltid 
finns för mig och min familj. Jag vet att jag kan räkna med dig och med Stig för allt! 
 
To my family-in-law: ni har blivit min stora familj! Tack för alla delade stunder, både här 
och där. Jag är evig tacksam till Alf och Ninni: tack för er gästfrihet från vårt allra första 
möte. Jag älskar att kunna njuta av att vara på ön. Tack Lisa och familj som vitnade 
spökliga blixt- och dundernätter. Tack Olle, Jonas, och Evelina för sommarminnen! 
Speciellt tack går till Andreas och Ann-Sofie, för många fina samtal tillsammans både i 
Sverige och i Spanien. Och en speciell uppskattning går till Ing-Marie och Erik för alla 
trivsamma och avkopplande stunder på Vätö.  
 
To my Spanish family: las raíces parece que nos atraen hacia esta hermosa tierra y rindo 
homenaje a mis abuelos y ancestros. Mi gratitud también al tío Dani y la tía Mari por 
darme tanta alegría y sentirlos tan cerca. Tía, ¡tú siempre fuiste el hombro en el que 
apoyarme! My sweet cousin Natalia and your beautiful family! Agradezco compartir 
durante años nuestras charlas y encuentros. Este último tiempo ha sido muy distinto y por 
eso doy mis aplausos por vuestra creación de la Radio de Anne y por tantos buenos ratos 
compartidos durante el confinamiento, ¡fue como si estuviésemos juntos!  
 
To my brother Lucas, for being such a lovely brother! Siempre estaremos unidos y 
agradezco tenerte cerquita, aunque nos separe la distancia física. Y qué precioso está siendo 
compartir esta nueva etapa de ser padres. Tu familia se ha convertido en la mía, y me llena 
de gratitud el tiempo compartido con Delfina y mi sobrina Luisa, ¡y esperemos que más 
rulos lleguen a nuestra familia!  
 
74 
To my dad, Daniel Cerqueiro, the first Dr. Cerqueiro in the family. Papá, te quedo 
agradecida por el traspaso del sentido del esfuerzo y del conocimiento de respeto, y de 
moral y ética. Con tus logros me has mostrado no solo el camino académico, sino también 
el de la responsabilidad del haber público. Como escritor me has servido de inspiración, por 
ejemplo, ayudándome en la parte histórica referida en esta tesis. También tu visión futurista 
me inspira y espero que juntos podamos averiguar qué nos depara la llegada de la nano-
tecnología. Asimismo, le doy las gracias a tu compañera de vida, Beatriz Zonzini. Bea, te 
agradezco por ser como una madre para mí, siempre cerca para ayudar y mediar. Gracias 
por haber aumentado mi capacidad deductiva durante las tardes de cartas. Los quiero tanto, 
y les agradezco también vuestro rol de abu Bilo y abu Bea, siempre tan cariñosos    . 
 
To my mother, Ana Bailon, my dearest and beloved mom! Mamá, sobre todas las cosas te 
doy las gracias por aceptarme y amarme tal como soy. Me has enseñado a dar de mí lo 
mejor que yo puedo. Mil gracias porque me escuchas, me apoyas y porque me das la 
fortaleza para seguir adelante. Estoy en gratitud porque entre otras cosas me transmitiste los 
valores estéticos, la música y la fotografía. Gracias por haber contribuido a este sueño 
español, y, sin dudar, me has dado un refugio donde concentrarme estos últimos meses 
escribiendo mi tesis. ¡Porque me has nutrido en el sentido implícito y en el intelectual!  
No me alcanza la vida para devolverte lo que me has otorgado. Mi amor y agradecimiento 
no tienen fin      . ¡Por siempre Mabu! 
 
To my husband Magnus. You are one of the most patient people I know, and you have 
been one of my greatest and nearest teachers! Jag älskar dig! Thank you for helping me in 
life and sharing so many happy moments with me. I am grateful for our choice to move to 
Spain , to allocate this new platform in gracefulness which created a prosperous home for 
our family. I am so grateful for your act of love by supporting me intensively these last 
months, and offering me the invaluable opportunity to give 100% focus in my writing.  
I hope I can return it, so you can focus on your project full-time! 
 
Last, but most importantly, to my beloved children. Mis queridas hijas: Alma y Alice, Uds. 
son lo mejor de mi vida y lo sabéis: Alma, mi estrellita  y Alice, mi solcito  . ¡Cuánto 
las quiero, hijitas! Gracias por todo lo compartido y por lo que vendrá, ¡y mil gracias por la 
paciencia! Vuestra energía, curiosidad y la sabiduría que lleváis dentro me derriten y me 
apasionan. Les brindo mi agradecimiento y amor infinito, y deseo que vuestros caminos se 




Finally, I would like to send my gratitude to several organizations for the scholarships and 
grants that had made this thesis possible. The studies included in this PhD project have 
received financial support from: 
• Barndiabetesfonden (The Swedish Childhood Diabetes Foundation) 
• The Swedish Diabetes Association's Aid Fund 
• The Council Skåne Research Foundation (ALF) 
• The Stockholm Medical Association 
• The Swedish Society of Medicine 
• The Swedish Celiac Association 
• Sällskapet barnavård 
• The Sigurd and Elsas Golje Memorial Foundation 
• The Samariten Foundation for Paediatric Research 
• The Swedish Society for Gastroenterology with Astra Zeneca 





1. Lyons AS, Petrucelli RJ. Medicine: an illustrated history. New York: Abrams; 1978. 
2. Peña AS, Rodrigo Saez L. Enfermedad celíaca y sensibilidad al gluten no celíaca. OmniaScience 
Monographs. 2013. 
3. Husby S, Koletzko S, Korponay-Szabo IR, et al. European Society for Pediatric Gastroenterology, 
Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 
2012;54(1):136-60. 
4. Hill ID, Fasano A, Guandalini S, et al. NASPGHAN Clinical Report on the Diagnosis and Treatment 
of Gluten-related Disorders. J Pediatr Gastroenterol Nutr. 2016;63(1):156-65. 
5. Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. 
Gut. 2013;62(1):43-52. 
6. Coronel Rodríguez C, AS RP, Guisado Rasco M. Enfermedad celíaca. Pediatr Integral. 
2019;23(8):392-405. 
7. Singh P, Arora A, Strand TA, et al. Global Prevalence of Celiac Disease: Systematic Review and 
Meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):823-36 e2. 
8. Choung RS, Larson SA, Khaleghi S, et al. Prevalence and Morbidity of Undiagnosed Celiac Disease 
From a Community-Based Study. Gastroenterology. 2017;152(4):830-9.e5. 
9. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 
2014;35(3):347-69. 
10. Ivarsson A, Myleus A, Norstrom F, et al. Prevalence of childhood celiac disease and changes in infant 
feeding. Pediatrics. 2013;131(3):e687-94. 
11. Namatovu F, Sandström O, Olsson C, et al. Celiac disease risk varies between birth cohorts, generating 
hypotheses about causality: evidence from 36 years of population-based follow-up. BMC 
Gastroenterol. 2014;14:59. 
12. Olsson C, Hernell O, Hornell A, et al. Difference in celiac disease risk between Swedish birth cohorts 
suggests an opportunity for primary prevention. Pediatrics. 2008;122(3):528-34. 
13. Unalp-Arida A, Ruhl CE, Choung RS, et al. Lower Prevalence of Celiac Disease and Gluten-Related 
Disorders in Persons Living in Southern vs Northern Latitudes of the United States. Gastroenterology. 
2017;152(8):1922-32.e2. 
14. Ludvigsson JF, Murray JA. Epidemiology of Celiac Disease. Gastroenterol Clin North Am. 
2019;48(1):1-18. 
15. King JA, Jeong J, Underwood FE, et al. Incidence of Celiac Disease Is Increasing Over Time:  
A Systematic Review and Meta-analysis. The American journal of gastroenterology. 2020;115(4): 
507-25. 
16. Myleus A, Ivarsson A, Webb C, et al. Celiac disease revealed in 3% of Swedish 12-year-olds born 
during an epidemic. J Pediatr Gastroenterol Nutr. 2009;49(2):170-6. 
17. Liu E, Lee H-S, Agardh D. Risk of celiac disease according to HLA haplotype and country. The New 
England journal of medicine NEJM. 2014;371(11):1074-. 
18. Ivarsson A, Persson LA, Nystrom L, et al. Epidemic of coeliac disease in Swedish children. Acta 
Paediatr. 2000;89(2):165-71. 
19. Ivarsson A, Persson LA, Nystrom L, et al. The Swedish coeliac disease epidemic with a prevailing 
twofold higher risk in girls compared to boys may reflect gender specific risk factors. Eur J Epidemiol. 
2003;18(7):677-84. 
20. Ivarsson A, Hogberg L, Stenhammar L. The Swedish Childhood Coeliac Disease Working Group after 
20 years: history and future. Acta Paediatr. 2010;99(9):1429-31. 
21. Laurin P, Stenhammar L, Fälth-Magnusson K. Increasing prevalence of coeliac disease in Swedish 
children: influence of feeding recommendations, serological screening and small intestinal biopsy 
activity. Scand J Gastroenterol. 2004;39(10):946-52. 
22. Husby S, Koletzko S, Korponay-Szabo I, et al. European Society Paediatric Gastroenterology, 
Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. J Pediatr Gastroenterol 
Nutr. 2020;70(1):141-56. 
23. Green PH, Rostami K, Marsh MN. Diagnosis of coeliac disease. Best Pract Res Clin Gastroenterol. 
2005;19(3):389-400. 
24. Collin P, Kaukinen K, Vogelsang H, et al. Antiendomysial and antihuman recombinant tissue 
transglutaminase antibodies in the diagnosis of coeliac disease: a biopsy-proven European multicentre 
study. Eur J Gastroenterol Hepatol. 2005;17(1):85-91. 
25. Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and 




26. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a 
standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999;11(10):1185-94. 
27. Oberhuber G. Histopathology of celiac disease. Biomed Pharmacother. 2000;54(7):368-72. 
28. Hallert C, Stenhammar L, Grehn S. Celiakiboken : om glutenintolerans. Stockholm: Gothia; 2005. 
29. Meuwisse G. Diagnostic criteria in coeliac disease. Acta Paediatr Scand.4:461. 
30. Walker-Smith JA GS, Schmitz J, et al. Revised criteria for diagnosis of coeliac disease. Report of 
Working Group of European Society of Paediatric Gastroenterology and Nutrition. Arch Dis Child. 
1990;65(8):909-11. 
31. Webb C, Halvarsson B, Norstrom F, et al. Accuracy in celiac disease diagnostics by controlling the 
small-bowel biopsy process. J Pediatr Gastroenterol Nutr. 2011;52(5):549-53. 
32. Ludvigsson JF, Green PH. Clinical management of coeliac disease. J Intern Med. 2011;269(6):560-71. 
33. Lentze MJ, Auricchio S, Cadranel S, et al. Chapter 2. ESPGHAN: 50 Years Memories-The Early 
Years. J Pediatr Gastroenterol Nutr. 2018;66 Suppl 1:S20-s8. 
34. Hill PG, Holmes GK. Coeliac disease: a biopsy is not always necessary for diagnosis. Aliment 
Pharmacol Ther. 2008;27(7):572-7. 
35. Vivas S, Ruiz de Morales JG, Riestra S, et al. Duodenal biopsy may be avoided when high 
transglutaminase antibody titers are present. World J Gastroenterol. 2009;15(38):4775-80. 
36. Murch S, Jenkins H, Auth M, et al. Joint BSPGHAN and Coeliac UK guidelines for the diagnosis and 
management of coeliac disease in children. Arch Dis Child. 2013;98(10):806-11. 
37. Webb C, Norstrom F, Myleus A, et al. Celiac disease can be predicted by high levels of anti-tissue 
transglutaminase antibodies in population-based screening. J Pediatr Gastroenterol Nutr. 
2015;60(6):787-91. 
38. Trovato CM, Montuori M, Anania C, et al. Are ESPGHAN "biopsy-sparing" guidelines for celiac 
disease also suitable for asymptomatic patients? The American journal of gastroenterology. 
2015;110(10):1485-9. 
39. Donat E, Ramos JM, Sanchez-Valverde F, et al. ESPGHAN 2012 Guidelines for Coeliac Disease 
Diagnosis: Validation Through a Retrospective Spanish Multicentric Study. J Pediatr Gastroenterol 
Nutr. 2016;62(2):284-91. 
40. Paul SP, Sandhu BK, Spray CH, et al. Evidence Supporting Serology-based Pathway for Diagnosing 
Celiac Disease in Asymptomatic Children From High-risk Groups. J Pediatr Gastroenterol Nutr. 
2018;66(4):641-4. 
41. Werkstetter KJ, Korponay-Szabo IR, Popp A, et al. Accuracy in Diagnosis of Celiac Disease Without 
Biopsies in Clinical Practice. Gastroenterology. 2017;153(4):924-35. 
42. Wolf J, Petroff D, Richter T, et al. Validation of Antibody-Based Strategies for Diagnosis of Pediatric 
Celiac Disease Without Biopsy. Gastroenterology. 2017;153(2):410-9 e17. 
43. U.S. Food and Drug Administration. Gluten and Food Labeling: U.S. Food and Drug Administration; 
2018 [Date Accessed: 17th November 2020. Available from: https://www.fda.gov/food/nutrition-
education-resources-materials/gluten-and-food-labeling 
44. EU. European Commission implementing regulation (EU) No 828/2014, requirements for the 
provision of information to consumers on the absence or reduced presence of gluten in food. Off J Eur 
Union L. 2014;228:5-8. 
45. Lindfors K, Ciacci C, Kurppa K, et al. Coeliac disease. Nat Rev Dis Primers. 2019;5(1):3. 
46. Caio G, Volta U, Sapone A, et al. Celiac disease: a comprehensive current review. BMC medicine. 
2019;17(1):142. 
47. Tye-Din JA, Galipeau HJ, Agardh D. Celiac Disease: A Review of Current Concepts in Pathogenesis, 
Prevention, and Novel Therapies. Frontiers in pediatrics. 2018;6:350. 
48. Verdu EF, Danska JS. Common ground: shared risk factors for type 1 diabetes and celiac disease.  
Nat Immunol. 2018;19(7):685-95. 
49. Sollid LM, Markussen G, Ek J, et al. Evidence for a primary association of celiac disease to a 
particular HLA-DQ alpha/beta heterodimer. J Exp Med. 1989;169(1):345-50. 
50. Sollid LM, Tye-Din JA, Qiao SW, et al. Update 2020: nomenclature and listing of celiac disease-
relevant gluten epitopes recognized by CD4(+) T cells. Immunogenetics. 2020;72(1-2):85-8. 
51. Fasano A, Catassi C. Clinical practice. Celiac disease. N Engl J Med. 2012;367(25):2419-26. 
52. Kuja-Halkola R, Lebwohl B, Halfvarson J, et al. Heritability of non-HLA genetics in coeliac disease:  
a population-based study in 107 000 twins. Gut. 2016;65(11):1793-8. 
53. Lundin KE, Qiao SW, Snir O, et al. Coeliac disease - from genetic and immunological studies to 
clinical applications. Scand J Gastroenterol. 2015;50(6):708-17. 
54. Interreg Central Europe. Focus in CD - Celiac Facts 2020 [Online Course “Celiac Facts” for 
Physicians & Dietitians]. Date Accessed: 2nd november 2020. Available from: https://celiacfacts-
onlinecourses.eu/course/view.php?id=36 




56. Caio G, Volta U, Sapone A, et al. Celiac disease: a comprehensive current review. BMC medicine. 
2019;17(1):142. 
57. Ludvigsson JF, Fasano A. Timing of introduction of gluten and celiac disease risk. Ann Nutr Metab. 
2012;60 Suppl 2:22-9. 
58. Lionetti E, Castellaneta S, Francavilla R, et al. Introduction of gluten, HLA status, and the risk of 
celiac disease in children. N Engl J Med. 2014;371(14):1295-303. 
59. Vriezinga SL, Auricchio R, Bravi E, et al. Randomized feeding intervention in infants at high risk for 
celiac disease. N Engl J Med. 2014;371(14):1304-15. 
60. Andren Aronsson C, Lee HS, Hard Af Segerstad EM, et al. Association of Gluten Intake During the 
First 5 Years of Life With Incidence of Celiac Disease Autoimmunity and Celiac Disease Among 
Children at Increased Risk. JAMA. 2019;322(6):514-23. 
61. Mårild K, Dong F, Lund-Blix NA, et al. Gluten Intake and Risk of Celiac Disease: Long-Term Follow-
up of an At-Risk Birth Cohort. The American journal of gastroenterology. 2019;114(8):1307-14. 
62. Lund-Blix NA, Dong F, Mårild K, et al. Gluten Intake and Risk of Islet Autoimmunity and Progression 
to Type 1 Diabetes in Children at Increased Risk of the Disease: The Diabetes Autoimmunity Study in 
the Young (DAISY). Diabetes Care. 2019;42(5):789-96. 
63. Dydensborg Sander S, Nybo Andersen AM, Murray JA, et al. Association Between Antibiotics in the 
First Year of Life and Celiac Disease. Gastroenterology. 2019;156(8):2217-29. 
64. Myleus A, Hernell O, Gothefors L, et al. Early infections are associated with increased risk for celiac 
disease: an incident case-referent study. BMC pediatrics. 2012;12:194. 
65. Vaarala O, Jokinen J, Lahdenkari M, et al. Rotavirus Vaccination and the Risk of Celiac Disease or 
Type 1 Diabetes in Finnish Children at Early Life. The Pediatric infectious disease journal. 
2017;36(7):674-5. 
66. Hemming-Harlo M, Lahdeaho ML, Maki M, et al. Rotavirus Vaccination Does Not Increase Type 1 
Diabetes and May Decrease Celiac Disease in Children and Adolescents. The Pediatric infectious 
disease journal. 2019;38(5):539-41. 
67. Schober E, Granditsch G. IDDM and celiac disease. Diabetes Care. 1994;17(12):1549-50. 
68. Mayer-Davis EJ, Kahkoska AR, Jefferies C, et al. ISPAD Clinical Practice Consensus Guidelines 
2018: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr 
Diabetes. 2018;19 Suppl 27(Suppl 27):7-19. 
69. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007;30 Suppl 
1:S42-7. 
70. Hanås R. Typ 1 diabetes hos barn, ungdomar och unga vuxna : hur du blir expert på din egen diabetes. 
[Uddevalla]: BetaMed; 2018. 
71. Dahlquist G, Mustonen L. Analysis of 20 years of prospective registration of childhood onset diabetes 
time trends and birth cohort effects. Swedish Childhood Diabetes Study Group. Acta Paediatr. 
2000;89(10):1231-7. 
72. Patterson CC, Dahlquist GG, Gyurus E, et al. Incidence trends for childhood type 1 diabetes in Europe 
during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. 
Lancet. 2009;373(9680):2027-33. 
73. Berhan Y, Waernbaum I, Lind T, et al. Thirty years of prospective nationwide incidence of childhood 
type 1 diabetes: the accelerating increase by time tends to level off in Sweden. Diabetes. 
2011;60(2):577-81. 
74. Dahlquist GG, Nystrom L, Patterson CC, et al. Incidence of type 1 diabetes in Sweden among 
individuals aged 0-34 years, 1983-2007: an analysis of time trends. Diabetes Care. 2011;34(8):1754-9. 
75. Diabetes.co.uk. Insulin History 2019 [Date Accessed: 22th of October 2020. Available from: 
https://www.diabetes.co.uk/insulin/history-of-insulin.html 
76. Bach JF, Chatenoud L. The hygiene hypothesis: an explanation for the increased frequency of insulin-
dependent diabetes. Cold Spring Harb Perspect Med. 2012;2(2):a007799. 
77. Wilkin TJ. The convergence of type 1 and type 2 diabetes in childhood: the accelerator hypothesis. 
Pediatr Diabetes. 2012;13(4):334-9. 
78. Ilonen J, Lempainen J, Veijola R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev 
Endocrinol. 2019;15(11):635-50. 
79. Krischer JP, Liu X, Vehik K, et al. Predicting Islet Cell Autoimmunity and Type 1 Diabetes: An 8-
Year TEDDY Study Progress Report. Diabetes Care. 2019;42(6):1051-60. 
80. Andersson C, Larsson K, Vaziri-Sani F, et al. The three ZNT8 autoantibody variants together improve 
the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity. 2011;44(5): 
394-405. 
81. Andersson C, Vaziri-Sani F, Delli A, et al. Triple specificity of ZnT8 autoantibodies in relation to 
HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes. Pediatr Diabetes. 
2013;14(2):97-105. 
82. Redondo MJ, Steck AK, Pugliese A. Genetics of type 1 diabetes. Pediatr Diabetes. 2018;19(3):346-53. 
 
78 
83. Concannon P, Erlich HA, Julier C, et al. Type 1 diabetes: evidence for susceptibility loci from four 
genome-wide linkage scans in 1,435 multiplex families. Diabetes. 2005;54(10):2995-3001. 
84. Noble JA. Immunogenetics of type 1 diabetes: A comprehensive review. J Autoimmun. 2015;64: 
101-12. 
85. Lambert AP, Gillespie KM, Thomson G, et al. Absolute risk of childhood-onset type 1 diabetes 
defined by human leukocyte antigen class II genotype: a population-based study in the United 
Kingdom. J Clin Endocrinol Metab. 2004;89(8):4037-43. 
86. Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. Lancet. 2016;387(10035):2331-9. 
87. Maziarz M, Hagopian W, Palmer JP, et al. Non-HLA type 1 diabetes genes modulate disease risk 
together with HLA-DQ and islet autoantibodies. Genes Immun. 2015;16(8):541-51. 
88. Akerblom HK, Vaarala O, Hyöty H, et al. Environmental factors in the etiology of type 1 diabetes.  
Am J Med Genet. 2002;115(1):18-29. 
89. Thorsen SU, Halldorsson TI, Bjerregaard AA, et al. Maternal and Early Life Iron Intake and Risk of 
Childhood Type 1 Diabetes: A Danish Case-Cohort Study. Nutrients. 2019;11(4). 
90. Hemming-Harlo M, Lähdeaho ML, Mäki M, et al. Rotavirus Vaccination Does Not Increase Type 1 
Diabetes and May Decrease Celiac Disease in Children and Adolescents. The Pediatric infectious 
disease journal. 2019;38(5):539-41. 
91. Glanz JM, Clarke CL, Xu S, et al. Association Between Rotavirus Vaccination and Type 1 Diabetes in 
Children. JAMA Pediatr. 2020;174(5):455-62. 
92. Walker-Smith JA, Grigor W. Coeliac disease in a diabetic child. Lancet. 1969;1(7603):1021. 
93. Hooft C, Devos E, Kriekemans J, et al. Malabsorption and diabetes mellitus in children. Helv Paediatr 
Acta. 1968;23(5):478-88. 
94. Walker-Smith JA. Diabetes and coeliac disease. Lancet. 1969;2(7634):1366. 
95. Hooft C, Devos E, Van Damme J. Coeliac disease in a diabetic child. Lancet. 1969;2(7612):161. 
96. Komrower GM. Coeliac disease in a diabetic child. Lancet. 1969;1(7607):1215. 
97. Sud S, Marcon M, Assor E, et al. Celiac disease and pediatric type 1 diabetes: diagnostic and treatment 
dilemmas. Int J Pediatr Endocrinol. 2010;2010:161285. 
98. Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. Aliment 
Pharmacol Ther. 2007;26(9):1217-25. 
99. Thain ME, Hamilton JR, Ehrlich RM. Coexistence of diabetes mellitus and celiac disease. J Pediatr. 
1974;85(4):527-9. 
100. Shanahan F, McKenna R, McCarthy CF, et al. Coeliac disease and diabetes mellitus: a study of 24 
patients with HLA typing. Q J Med. 1982;51(203):329-35. 
101. Lie BA, Sollid LM, Ascher H, et al. A gene telomeric of the HLA class I region is involved in 
predisposition to both type 1 diabetes and coeliac disease. Tissue Antigens. 1999;54(2):162-8. 
102. Kurppa K, Laitinen A, Agardh D. Coeliac disease in children with type 1 diabetes. Lancet Child 
Adolesc Health. 2018;2(2):133-43. 
103. Fröhlich-Reiterer EE, Hofer S, Kaspers S, et al. Screening frequency for celiac disease and 
autoimmune thyroiditis in children and adolescents with type 1 diabetes mellitus--data from a 
German/Austrian multicentre survey. Pediatr Diabetes. 2008;9(6):546-53. 
104. Rami B, Sumnik Z, Schober E, et al. Screening detected celiac disease in children with type 1 diabetes 
mellitus: effect on the clinical course (a case control study). J Pediatr Gastroenterol Nutr. 
2005;41(3):317-21. 
105. Hansen D, Brock-Jacobsen B, Lund E, et al. Clinical benefit of a gluten-free diet in type 1 diabetic 
children with screening-detected celiac disease: a population-based screening study with 2 years' 
follow-up. Diabetes Care. 2006;29(11):2452-6. 
106. Sanchez-Albisua I, Wolf J, Neu A, et al. Coeliac disease in children with Type 1 diabetes mellitus: t 
he effect of the gluten-free diet. Diabet Med. 2005;22(8):1079-82. 
107. Jones HJ, Warner JT. NICE clinical guideline 86. Coeliac disease: recognition and assessment of 
coeliac disease. Archives of Disease in Childhood. 2010;95(4):312. 
108. Babiker A, Morris MA, Datta V. Coeliac disease and type 1 diabetes: 7 years experience versus NICE 
guidance 2009. Arch Dis Child. 2010;95(12):1068-9. 
109. Richey R, Howdle P, Shaw E, et al. Recognition and assessment of coeliac disease in children and 
adults: summary of NICE guidance. Bmj. 2009;338:b1684. 
110. National Institute for Health and Care Excellence. Coeliac disease: recognition, assessment and 
management 2020 [Date Accessed: 5th November 2020. Available from: 
https://www.nice.org.uk/guidance/ng20/chapter/Recommendations#ftn.footnote_3  
111. Kordonouri O, Maguire AM, Knip M, et al. ISPAD Clinical Practice Consensus Guidelines 2006-
2007. Other complications and associated conditions. Pediatr Diabetes. 2007;8(3):171-6. 
112. Mahmud FH, Elbarbary NS, Fröhlich-Reiterer E, et al. ISPAD Clinical Practice Consensus Guidelines 
2018: Other complications and associated conditions in children and adolescents with type 1 diabetes. 
Pediatr Diabetes. 2018;19 Suppl 27(Suppl 27):275-86. 
113. Wilson JMG, Jungner G, Organization WH. Principles and practice of screening for disease. 1968. 
 
 79 
114. Kivelä L, Kurppa K. Screening for coeliac disease in children. Acta Paediatr. 2018;107(11):1879-87. 
115. Silink M. How should we manage celiac disease in childhood diabetes? Pediatr Diabetes. 
2001;2(3):95-7. 
116. Sigurs N, Johansson C, Elfstrand PO, et al. Prevalence of coeliac disease in diabetic children and 
adolescents in Sweden. Acta Paediatr. 1993;82(9):748-51. 
117. Carlsson AK, Axelsson IE, Borulf SK, et al. Prevalence of IgA-antiendomysium and IgA-antigliadin 
autoantibodies at diagnosis of insulin-dependent diabetes mellitus in Swedish children and adolescents. 
Pediatrics. 1999;103(6 Pt 1):1248-52. 
118. Larsson K, Carlsson A, Cederwall E, et al. Annual screening detects celiac disease in children with 
type 1 diabetes. Pediatr Diabetes. 2008;9(4 Pt 2):354-9. 
119. Hansson T, Dahlbom I, Tuvemo T, et al. Silent coeliac disease is over-represented in children with 
type 1 diabetes and their siblings. Acta Paediatr. 2015;104(2):185-91. 
120. Kaur N, Bhadada SK, Minz RW, et al. Interplay between Type 1 Diabetes Mellitus and Celiac Disease: 
Implications in Treatment. Dig Dis. 2018;36(6):399-408. 
121. Camarca ME, Mozzillo E, Nugnes R, et al. Celiac disease in type 1 diabetes mellitus. Ital J Pediatr. 
2012;38:10. 
122. Elfström P, Sundström J, Ludvigsson JF. Systematic review with meta-analysis: associations between 
coeliac disease and type 1 diabetes. Aliment Pharmacol Ther. 2014;40(10):1123-32. 
123. Pham-Short A, Donaghue KC, Ambler G, et al. Screening for Celiac Disease in Type 1 Diabetes:  
A Systematic Review. Pediatrics. 2015;136(1):e170-6. 
124. Adlercreutz EH, Wingren CJ, Vincente RP, et al. Perinatal risk factors increase the risk of being 
affected by both type 1 diabetes and coeliac disease. Acta pædiatrica. 2015;104(2):178-84. 
125. Pundziute-Lycka A, Urbonaite B, Dahlquist G. Infections and risk of Type I (insulin-dependent) 
diabetes mellitus in Lithuanian children. Diabetologia. 2000;43(10):1229-34. 
126. Ludvigsson JF, Montgomery SM, Ekbom A, et al. Small-intestinal histopathology and mortality risk in 
celiac disease. JAMA. 2009;302(11):1171-8. 
127. Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac 
disease. Gastroenterology. 2009;137(1):88-93. 
128. Olen O, Askling J, Ludvigsson JF, et al. Coeliac disease characteristics, compliance to a gluten free 
diet and risk of lymphoma by subtype. Dig Liver Dis. 2011;43(11):862-8. 
129. Carlsson A, Agardh D, Borulf S, et al. Prevalence of celiac disease: before and after a national change 
in feeding recommendations. Scand J Gastroenterol. 2006;41(5):553-8. 
130. Smyth DJ, Plagnol V, Walker NM, et al. Shared and distinct genetic variants in type 1 diabetes and 
celiac disease. N Engl J Med. 2008;359(26):2767-77. 
131. Popp A, Mihu M, Munteanu M, et al. Prospective antibody case finding of coeliac disease in type-1 
diabetes children: need of biopsy revisited. Acta Paediatr. 2013;102(3):e102-6. 
132. Statistical database [Internet]. SCB, Statistics Sweden. 2020 [Date Accessed: 21 Sept 2020]. Available 
from: http://www.statistikdatabasen.scb.se/pxweb/en/ssd/. 
133. WHO. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a 
WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. World Health 
Organization; 1999. 
134. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national 
inpatient register. BMC Public Health. 2011;11:450. 
135. Emilsson L, Lindahl B, Koster M, et al. Review of 103 Swedish Healthcare Quality Registries. J Intern 
Med. 2015;277(1):94-136. 
136. Persson M, Becker C, Elding Larsson H, et al. The Better Diabetes Diagnosis (BDD) study -  
A review of a nationwide prospective cohort study in Sweden. Diabetes research and clinical practice. 
2018;140:236-44. 
137. Wong RC, Wilson RJ, Steele RH, et al. A comparison of 13 guinea pig and human anti-tissue 
transglutaminase antibody ELISA kits. Journal of clinical pathology. 2002;55(7):488-94. 
138. Kiviniemi M, Hermann R, Nurmi J, et al. A high-throughput population screening system for the 
estimation of genetic risk for type 1 diabetes: an application for the TEDDY (the Environmental 
Determinants of Diabetes in the Young) study. Diabetes technology & therapeutics. 2007;9(5):460-72. 
139. Sollid LM, Qiao SW, Anderson RP, et al. Nomenclature and listing of celiac disease relevant gluten  
T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics. 2012;64(6):455-60. 
140. Ludvigsson JF, Brandt L, Montgomery SM, et al. Validation study of villous atrophy and small 
intestinal inflammation in Swedish biopsy registers. BMC Gastroenterol. 2009;9:19. 
141. Grubin CE, Daniels T, Toivola B, et al. A novel radioligand binding assay to determine diagnostic 
accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. 
Diabetologia. 1994;37(4):344-50. 
142. Williams AJ, Bingley PJ, Bonifacio E, et al. A novel micro-assay for insulin autoantibodies.  
J Autoimmun. 1997;10(5):473-8. 
 
80 
143. Vaziri-Sani F, Delli AJ, Elding-Larsson H, et al. A novel triple mix radiobinding assay for the three 
ZnT8 (ZnT8-RWQ) autoantibody variants in children with newly diagnosed diabetes. J Immunol 
Methods. 2011;371(1-2):25-37. 
144. World Medical Association Declaration of Helsinki: ethical principles for medical research involving 
human subjects. Jama. 2013;310(20):2191-4. 
145. Hansen D, Bennedbaek FN, Hansen LK, et al. High prevalence of coeliac disease in Danish children 
with type I diabetes mellitus. Acta Paediatr. 2001;90(11):1238-43. 
146. Ashabani A, Abushofa U, Abusrewill S, et al. The prevalence of coeliac disease in Libyan children 
with type 1 diabetes mellitus. Diabetes Metab Res Rev. 2003;19(1):69-75. 
147. Bhadada SK, Rastogi A, Agarwal A, et al. Comparative study of clinical features of patients with 
celiac disease & those with concurrent celiac disease & type 1 diabetes mellitus. Indian J Med Res. 
2017;145(3):334-8. 
148. Saadah OI, Zacharin M, O'Callaghan A, et al. Effect of gluten-free diet and adherence on growth and 
diabetic control in diabetics with coeliac disease. Arch Dis Child. 2004;89(9):871-6. 
149. Boudraa G, Hachelaf W, Benbouabdellah M, et al. Prevalence of coeliac disease in diabetic children 
and their first- degree relatives in west Algeria: screening with serological markers. Acta Paediatr 
Suppl. 1996;412:58-60. 
150. Chou R, Bougatsos C, Blazina I, et al. Screening for Celiac Disease: Evidence Report and Systematic 
Review for the US Preventive Services Task Force. JAMA. 2017;317(12):1258-68. 
151. Andren Aronsson C, Kurppa K, Agardh D. Gluten in infants and celiac disease risk. Expert Rev 
Gastroenterol Hepatol. 2016;10(6):669-70. 
152. Andren Aronsson C, Lee HS, Koletzko S, et al. Effects of Gluten Intake on Risk of Celiac Disease:  
A Case-Control Study on a Swedish Birth Cohort. Clin Gastroenterol Hepatol. 2016;14(3):403-9 e3. 
153. Aronsson CA, Lee HS, Liu E, et al. Age at gluten introduction and risk of celiac disease. Pediatrics. 
2015;135(2):239-45. 
154. Ludvigsson JF, Lebwohl B. Three papers indicate that amount of gluten play a role for celiac disease - 
But only a minor role. Acta Paediatr. 2020;109(1):8-10. 
155. Alshiekh S, Maziarz M, Geraghty DE, et al. High-resolution genotyping suggests that children with 
type 1 diabetes and celiac disease share three HLA class II loci in DRB3, DRB4, and DRB5 genes. 
HLA. 2020. 
156. Alshiekh S, Zhao LP, Lernmark A, et al. Different DRB1*03:01-DQB1*02:01 haplotypes confer 
different risk for celiac disease. HLA. 2017;90(2):95-101. 
157. Delli AJ, Lindblad B, Carlsson A, et al. Type 1 diabetes patients born to immigrants to Sweden 
increase their native diabetes risk and differ from Swedish patients in HLA types and islet 
autoantibodies. Pediatr Diabetes. 2010;11(8):513-20. 
158. De Silvestri A, Capittini C, Poddighe D, et al. HLA-DQ genetics in children with celiac disease:  
a meta-analysis suggesting a two-step genetic screening procedure starting with HLA-DQ β chains. 
Pediatr Res. 2018;83(3):564-72. 
159. Elitsur Y, Sigman T, Watkins R, et al. Tissue Transglutaminase Levels Are Not Sufficient to Diagnose 
Celiac Disease in North American Practices Without Intestinal Biopsies. Digestive diseases and 
sciences. 2017;62(1):175-9. 
160. Castellaneta S, Piccinno E, Oliva M, et al. High rate of spontaneous normalization of celiac serology in 
a cohort of 446 children with type 1 diabetes: a prospective study. Diabetes Care. 2015;38(5):760-6. 
161. Simmons JH, Klingensmith GJ, McFann K, et al. Celiac autoimmunity in children with type 1 
diabetes: a two-year follow-up. J Pediatr. 2011;158(2):276-81 e1. 
162. Simell S, Hoppu S, Hekkala A, et al. Fate of five celiac disease-associated antibodies during normal 
diet in genetically at-risk children observed from birth in a natural history study. The American journal 
of gastroenterology. 2007;102(9):2026-35. 
163. Waisbourd-Zinman O, Hojsak I, Rosenbach Y, et al. Spontaneous normalization of anti-tissue 
transglutaminase antibody levels is common in children with type 1 diabetes mellitus. Digestive 
diseases and sciences. 2012;57(5):1314-20. 
164. Fernández-Bañares F, Arau B, Dieli-Crimi R, et al. Systematic Review and Meta-analysis Show 3% of 
Patients With Celiac Disease in Spain to be Negative for HLA-DQ2.5 and HLA-DQ8. Clin 
Gastroenterol Hepatol. 2017;15(4):594-6. 
165. Mitchell RT, Sun A, Mayo A, et al. Coeliac screening in a Scottish cohort of children with type 1 
diabetes mellitus: is DQ typing the way forward? Arch Dis Child. 2016;101(3):230-3. 
166. Bodd M, Tollefsen S, Bergseng E, et al. Evidence that HLA-DQ9 confers risk to celiac disease by 
presence of DQ9-restricted gluten-specific T cells. Human immunology. 2012;73(4):376-81. 
167. Wessels M, Velthuis A, van Lochem E, et al. Raising the Cut-Off Level of Anti-Tissue 
Transglutaminase Antibodies to Detect Celiac Disease Reduces the Number of Small Bowel Biopsies 
in Children with Type 1 Diabetes: A Retrospective Study. J Pediatr. 2020;223:87-92 e1. 
168. Joshi KK, Haynes A, Davis EA, et al. Role of HLA-DQ typing and anti-tissue transglutaminase 
antibody titers in diagnosing celiac disease without duodenal biopsy in type 1 diabetes: A study of the 
 
 81 
population-based pediatric type 1 diabetes cohort of Western Australia. Pediatr Diabetes. 
2019;20(5):567-73. 
169. Punales M, Bastos MD, Ramos ARL, et al. Prevalence of celiac disease in a large cohort of young 
patients with type 1 diabetes. Pediatr Diabetes. 2019;20(4):414-20. 
170. Burgin-Wolff A, Dahlbom I, Hadziselimovic F, et al. Antibodies against human tissue 
transglutaminase and endomysium in diagnosing and monitoring coeliac disease. Scand J 
Gastroenterol. 2002;37(6):685-91. 
171. Maki M, Mustalahti K, Kokkonen J, et al. Prevalence of Celiac disease among children in Finland.  
N Engl J Med. 2003;348(25):2517-24. 
172. Donat E, Roca M, Masip E, et al. Common Problems Found in the Methodological Approach to Small 
Bowel Biopsies in the Diagnosis of Celiac Disease. J Pediatr Gastroenterol Nutr. 2019;69(3):336-8. 
173. Rinawi F, Badarneh B, Tanous O, et al. Elevated anti-tissue transglutaminase antibodies in children 
newly diagnosed with type 1 diabetes do not always indicate coeliac disease. Acta Paediatr. 
2019;108(1):149-53. 
174. Mubarak A, Spierings E, Wolters VM, et al. Children with celiac disease and high tTGA are 
genetically and phenotypically different. World J Gastroenterol. 2013;19(41):7114-20. 
175. Glastras SJ, Craig ME, Verge CF, et al. The role of autoimmunity at diagnosis of type 1 diabetes in the 
development of thyroid and celiac disease and microvascular complications. Diabetes Care. 
2005;28(9):2170-5. 
176. Kakleas K, Karayianni C, Critselis E, et al. The prevalence and risk factors for coeliac disease among 
children and adolescents with type 1 diabetes mellitus. Diabetes research and clinical practice. 2010. 
177. Pham-Short A, Donaghue KC, Ambler G, et al. Coeliac disease in Type 1 diabetes from 1990 to 2009: 
higher incidence in young children after longer diabetes duration. Diabet Med. 2012;29(9):e286-9. 
178. Cerutti F, Bruno G, Chiarelli F, et al. Younger age at onset and sex predict celiac disease in children 
and adolescents with type 1 diabetes: an Italian multicenter study. Diabetes Care. 2004;27(6):1294-8. 
179. Craig ME, Prinz N, Boyle CT, et al. Prevalence of Celiac Disease in 52,721 Youth With Type 1 
Diabetes: International Comparison Across Three Continents. Diabetes Care. 2017;40(8):1034-40. 
180. Crone J, Rami B, Huber WD, et al. Prevalence of celiac disease and follow-up of EMA in children and 
adolescents with type 1 diabetes mellitus. J Pediatr Gastroenterol Nutr. 2003;37(1):67-71. 
 
